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ABSTRACT 
In the past decade, a large number of naturally occuring thiazole and oxazole-
containing peptides have been isolated from microbial and marine origins. 
These peptides exhibit important antimicrobial, antiviral, and anticancer 
activities. Solid phase synthesis of peptides provides the methods to prepare 
and investigate novel compounds for possible use as antibiotics. Three 
combinatorial peptide libraries, library 1, an enantiomeric peptide library, 
library 2, with guanidinium, thiazole and benzothiophene side chains and 
library 3, designed from a template natural product, microcin Bl 7, were tested 
against Vibrio anguillarum (wild type), Escherichia coli (ZK 4) and 
Saccharomyces cerevisiae in zone inhibition and cell culture growth inhibition 
assays. Library 2, with guanidinium, thiazole and benzothiophene side chains 
exhibited significant antimicrobial activity towards V anguillarum and E. coli, 
with greater activity than did the enantiomeric peptide library, library 1, or the 
library based on microcin Bl 7, library 3. a-Helical antimicrobial peptides act 
by general permeabilization of bacterial membranes. Pleurocidin, a 25 amino 
acid peptide was extracted from the skin secretions of winter flounder. 
Pleurocidin is histidine rich, forms a well-defined amphipathic a-helix and 
exhibits no toxicity towards eukaryotic cells. Two novel C-terminally 
truncated pleurocidin amide peptides were synthesized by Solid Phase Peptide 
Synthesis (SPPS) and their identities were confirmed by Matrix Assisted Laser 
Desorption Ionization Mass Spectrometry (MALDl-TOF MS). The 
antimicrobial activities of the two C-terminally truncated peptides were 
11 
compared to pleurocidin amide against E. coli (ZK 4) and V angu.illarum. 
Methyl 2-S-(1 '-Boc-2'-phenylethyl) thiazole-4-carboxylate can be used as a 
useful building block in combinatorial peptide libraries. A convenient 
synthesis of methyl 2-S- (1 '-Boc-2'-phenylethyl) thiazole-4-carboxylate was 
developed. The synthetic scheme was based on the formation of the aldehyde 
from Boe-phenylalanine via reduction of N-methoxy-N-methylphenylalanine. 
Condensation of the resulting Boc-phenylalaninal with L-cysteine methyl ester 
yielded methyl 2-(1 '-Boc-phenylethyl) thiazolidine-4-carboxylate in good 
yield. Subsequent oxidation by activated Mn02 afforded methyl 2-(1 '-Boc-2'-
phenylethyl) thiazole-4-carboxylate but the yields were much lower. 
Topoisomerases are a class of enzymes that catalyzed topological 
interconversions of supercoiled DNA. Inhibition of topoisomerases I or II is a 
target for many anticancer drugs. DNA gyrase is a type II topoisomerase 
unique to bacteria, and inhibition of DNA gyrase is a target for selective 
antimicrobial agents. Sixteen compounds of tetrapeptide library 2 were 
screened for their topoisomerase I, and II inhibition. The inhibition assay 
depended on the differential migration of supercoiled DNA versus relaxed 
DNA. The results were inconclusive. 
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PREFACE 
Many pathogenic micro-organisms are resistant to the existing antibiotics. The 
increasing resistance problem has prompted the search of new antimicrobial 
agents with novel mechanisms of action to which the pathogenic micro-
organisms show little resistance. In the past decade, a large number of thiazole 
and oxazole containing natural products have been isolated from marine and 
insect origins that show important anticancer, antiviral and antimicrobial 
activities. 
This thesis presents information on the design, synthesis and analysis of three 
combinatorial peptide libraries and a series of C-truncated pleurocidin amide 
peptides. The manuscript format was adopted for the thesis presentation 
according to the guidelines of the Graduate School of University of Rhode 
Island. The thesis is composed of three chapters, one appendix and a 
bibliography. 
Chapter 1, "Antimicrobial activities of combinatorial peptide libraries", 
presents information on the antimicrobial activities of three combinatorial 
libraries with unnatural, thiazole and oxazole containing, amino acid building 
blocks. In this chapter, the three combinatorial libraries were tested against 
Vibrio anguillarum (wild type), Escherichia coli (ZK 4), a microcin-sensitive 
strain, and Saccharomyces cerevisiae (wild type) in both zone inhibition assays 
and cell culture growth inhibition assays. 
Chapter 2, "Antimicrobial activities of pleurocidin amide and related peptides 
truncated at the C-terminus", presents information on the design, synthesis and 
v 
antimicrobial activities of a series of C-terminus truncated pleurocidin amide 
peptides. 
Chapter 3, " Synthesis of novel thiazole-containing building blocks for 
combinatorial synthesis", describes the synthetic procedure employed to 
synthesize useful building blocks for combinatorial peptide libraries. 
Appendix, " Topo I, II Inhibition of a tetrapeptide library'', describes initial 
experiments towards characterization of topoisomerase I and topoisomerase II 
inhibition by a tetrapeptide library. 
A total bibliography of all the articles referred to in the thesis is also presented. 
Vl 
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CHAPTER 1: ANTIMICROBIAL ACTIVITY OF COMBINATORIAL 
PEPTIDE LIBRARIES 
ABSTRACT 
In the past decade, a large number of naturally occuring thiazole and oxazole-
containing peptides have been isolated from microbial and marine origins. 
These peptides exhibit important antimicrobial, antiviral, and anticancer 
activities. Heterocyclic rings alter peptide backbone connectivity and create 
new recognition surfaces for interaction with proteins, DNA and RNA. The 
thiazolidine and bisthiazole moieties are essential for the antimicrobial 
activities of bacitracin and bleomycin A2 respectively. 
Given th~ structural importance of thiazole and oxazole rings, three 
combinatorial peptide libraries with unnatural thiazole and oxazole-containing 
amino acid building blocks have been screened for their antimicrobial 
activities against the gram negative bacteria Escherichia coli (ZK. 4), a 
microcin-sensitive strain, Vibrio anguillarum (wild type) and the yeast 
Saccharomyces cerevisiae (wild type). The Minimum Inhibitory 
Concentration (MIC) values were determined by a cell culture growth 
inhibition assay. 
A library of tetrapeptides with guanidinium, thiazole, and benzothiophene side 
chains had higher potency (lower MIC values) against the candidate micro-
organisms than did an enantiomeric library of thiazolylalanine building blocks 
or a library of designed analogs of a natural antimicrobial peptide, (microcin 
Bl 7). 
The increased positive charge and the presence ofbenzothiophene side chains, 
which have the ability to intercalate between DNA base pairs may have 
contributed to the enhanced antimicrobial activity. 
Based on these results, it is recommended that future combinatorial peptide 
libraries should be designed to increase the number of positive charges and the 
number of building blocks with benzothiophene side chains. 
1.1 INTRODUCTION 
In the past decade, a large number of thiazole and oxazole-containing peptides 
have been isolated from microbial and marine origins. These peptides exhibit 
important antiviral, anticancer, antibacterial and antifungal activities<1>. GE 
2270 A (Figure 1.1. l) has been isolated from the fermentation broth of a strain 
of the fungus Planobispora rosea and inhibits bacterial protein synthesis<2>. 
Lyngbyabellin A (Figure 1.1.2) is a cytotoxic hexapeptide from the marine 
cyanobacterium Lyngbya majuscuza<3). BE 10988 (Figure 1.1.3) has been 
isolated from the culture broth of a strain of actinomycetes and was shown to 
inhibit topoisomerase Jf4)_ Haligramides A and B (Figure 1.1.4) are cytotoxic 
peptides from the marine sponge Haliclona nigra<5). Bacitracin (Figure 1.1.5) 
was isolated from the fermentation broth of Bacillus sp. and is currently used 
as a topical antibiotic<6). Patellamide F (Figure 1.1.6) is a new cytotoxic cyclic 
peptide from the colonial ascidian Lissoclinum patella<7) . Microcins are a 
group of small molecular weight peptides secreted from enterobacteriaceae. 
Microcin B 17 (Figure 1.1. 7) is secreted by certain strains of E. coli and kills 
susceptible bacteria by inhibiting DNA gyrase<S) . 
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Figure 1.1 Structures of thiazole/oxazole containing natural products 
A plausible mechanism for the formation of the heterocycles in vivo involves 
the condensation of the side chains of threonine, serine and cysteine onto the 
preceding carbonyl group to form oxazoline and thiazoline moieties, that can 
either undergo a two-electron oxidation to yield the heteroaromatic oxazoles 
and thiazoles, or a tw~lectron reduction to yield oxazolidines and 
thiazolidines (Figure 1.2)<9>. 
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Figure 1.2 Proposed mechanism ofheterocycle formation in natural products<9> 
Patterns of enzymatic heterocyclization have emerged in the past few years, 
and at least two types of enzyme systems are known. One type is exemplified 
by bacitracin synthetase, a non ribosomal peptide synthetase that assembles the 
growing product chain as an acyl-enzyme complex covalenty linked to the 
enzyme during initiation, elongation and termination<10). 
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Another example is the post-translational modification of microcin B 17 
(Figure 1.3)<11 >. 
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Figure 1.3 Biosynthesis ofMicrocin Bl 7<11 > 
Seven genes -mcb A-G, clustered in an operon are necessary and sufficient for 
microcin production. The 69 residue Mcb A polypeptide (also known as 
PreproMicrocin B 1 7) is a substrate for the enzyme microcin synthetase 
6 
composed of Mcb B, C and D subunits which introduces the eight heterocycles 
and converts Mcb A to inactive promicrocin Bl 7<12>. Subsequent proteolytic 
cleavage of the first 26 amino acids yields mature microcin Bl7<13>. Mcb E, 
and F act as an ATP-dependant export pump that secretes active microcin B 17 
into the medium<14>_ Microcin B 17 is taken up by both producer and 
recipient E. coli cells with the help of membrane proteins. 
Producer cells express mcb G and gain protection against microcin effects, 
recipient cells lack mcb G and accumulate DNA double strand breaks that lead 
to cell death<15>. 
Physiological effects of microcin B 17 include the inhibition of 
sernicons~rvative DNA replication. Inhibition of DNA replication induces the 
SOS response, which results in massive DNA degradation<16>. The molecular 
target for microcin Bl 7 is DNA gyrase<16>. 
DNA gyrase is a type II topoisomerase. DNA gyrase is specific to 
prokaryotes, which makes it an attractive site for the selective activity of 
antibiotics<11>. DNA gyrase controls the level of DNA supercoiling, catalizes 
double strand breaks in an ATP-dependant reaction, relaxes supercoiled DNA 
and re-ligates the cut strands<18>. E. coli DNA gyrase is an A2B2 tetramer. Gyr 
A is responsible for DNA cleavage and religation, Gyr B is responsible for the 
ATPase activity<19>_ Other known DNA gyrase inhibitors include coumarins 
like coumem1ycin A1 and novobiocin that compete with ATP for binding to 
the enzyme, and fluoroquinolones like ciprofloxacin<20> that binds the DNA-
enzyme complex. 
7 
; 
{i 
The mechanism by which microcin B 17 inhibits DNA gyrase is similar to that 
of ciprofloxacin. It is hypothesized that microcin B 17 traps the covalent DNA-
enzyme complex, slows down the enzyme and causes dissociation of the 
enzyme from the DNA, leaving the DNA double strands permanently cu{21 >. It 
remains to be shown that the bisheterocycle moieties in rnicrocin B 17 
intercalate between DNA base pairs which can effectively localize the 
compound and explains how it inhibits DNA gyrase. 
Heterocyclic rings alter peptide backbone connectivity and create new 
recognition surfaces for interaction with proteins, DNA and RNA. 
The thiazoline functionality is essential to the antibiotic activity of bacitracin. 
Bacitracin inhibits the incorporation of peptidoglycan strands into bacterial cell 
walls. The thiazoline ring ofbacitracin forms a divalent-metal ion-bridged 
complex with C55 - isoprenyl pyrophosphate, preventing C55 - isoprenyl 
pyrophosphate from ferrying disaccharide pentapeptides to their sites of 
attachment on the cell wa11C22>. 
The bisthiazole moiety in Bleomycin A2 intercalates between stacked DNA 
base pairs leading to an increased local concentration of the drug, leading 
ultimately to double strand cleavage of DNA, which accounts for its anticancer 
activity<23>. 
The synthetic combinatorial library (SCL) is a powerful tool for drug 
discovery. The combinatorial drug discovery process comprises the 
simultaneous generation of a large number of compounds by the systematic 
connection of a set of building blocks to form a library and screening of these 
compounds with their targets to identify novel compounds with enhanced 
8 
activity<24>. Solid phase peptide synthesis (SPPS) has allowed the synthesis of 
a large number of peptides simultaneously attached to a polymeric bead. Each 
bead contains only one peptide species. Combinatorial peptide library 
technology has been previously employed in designing inhibitors of 
chemotrypsin<25>, and to identify substrates that bind tyrosine kinase <26>. 
Given the structural importance of thiazole and oxazole heterocycles, synthetic 
combinatorial libraries with unnatural amino acid building blocks containing 
thiazole and oxazole heterocycles in the backbone of the peptide or on the side 
chains can be designed and their antimicrobial activities can be investigated. 
Library 1 is an enantiomeric tetrapeptide library made of two building blocks, 
L-3- ( 4 .. thiazolyl) alanine and D-3- ( 4-thiazolyl) alanine<21>. 
0 
II 
HO-C 
H 
H 
f J 
s 
Boc-L-3-(4-thiazolyl) alanine (L). Boc-D-3-(4-thiazolyl) alanine (D). 
Figure 1.4 The building blocks used to synthesize library 1<21>. 
The sequences of compounds in library 1 are shown in table 1.1. 
9 
Compound Sequence Compound Sequence 
L1 1 DDDD-NH2 L1 9 DLLL-NH2 
L12 DDDL-NH2 L1 10 DLDL-NH2 
L1 3 LDDL-NH2 L1 11 LLDL-NH2 
L14 LDDD-NH2 L1 12 LLLL-NH2 
L1 5 DDLL-NH2 L1 13 DLDD-NH2 
L16 DDLD-NH2 L1 14 DLLD-NH2 
L17 LDLL-NH2 L1 15 LLLD-NH2 
L1 8 LDLD-NH2 L1 16 LLDD-NH2 
Table 1.1: Library 1, (MW=634.11) from building blocks shown in Figure 1.4. 
Library i is a tetrapeptide library of 16 compounds. Library 2 design included 
a greater number of amino acid building blocks with heterocyclic side chains, 
such as imidazole (H) and benzothiophene (S). Arginine (R) was introduced to 
increase the overall positive charge on the tetrapeptidescis). 
Increasing the positive charge on the tetrapeptides may increase their transport 
across negatively charged bacterial membranes as well as increasing their 
binding affinities to DNA backbones. 
The sequences of the designed peptides comprising combinatorial library 2 are 
shown in Figure 1.5. 
10 
D-3-( 4-thiazolyl) alanine (D) L-arginine (R) L-3-(3-benzothienyl) alanine (S) 
L-histidine (H) L-3-( 4-thiazolyl) alanine (L) 
Figure 1.5 The structures of the building blocks oflibrary 2 
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Compound Sequence M.W., Compound Sequence 
g. /mol. 
L1 1 RSSS-NH2 783.5 L19 SSSR-NH2 
L12 RLSS-NH2 734.4 L1 10 SLSR-NH2 
L13 RDSS-NH2 734.4 L1 11 SDSR-NH2 
L14 RHSS-NH2 717.6 L1 12 SHSR-NH2 
L15 RSSH-NH2 717.6 L1 13 SSHR-NH2 
L16 RLSH-NH2 668.5 Li 14 SLHR-NH2 
L17 RDSH-NH2 668.5 L1 15 SDHR-NH2 
L18 RHSH-NH2 651.7 L1 16 SHHR-NH2 
Table 1.2 Library 2<28), tetrapeptide amides from building blocks shown in 
Figure 1.5. 
Library 3 was designed to assess the importance of thiazole and oxazole 
moieties in the overall antimicrobial activity of microcin B 17 (figure 1.1 . 7). 
2-Aminomethyl-thiazole-4-carboxylic acid (A) 2-Aminomethyl-oxazole-4-
carboxylic acid (B) 
O~ /Sil _ H2N 0N)>---\'N .lyOH 
0 
2-(2'-Aminomethyl-oxazole-4 '-yl)-thiazole-4-carboxylic acid (C) 
Glycine (G) 
Figure 1.6 The structures of the building blocks oflibrary 3. 
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M. W., 
g./mol. 
783.5 
734.4 
734.4 
717.6 
717.6 
668.5 
668.5 
651.7 
Compound Sequence M.W., g. I 
mol. 
LJ 1 .A.c-.A.CJ.A.-NlI-(C::II2)3-NlI2 454.2 
L3 2 .A.c-B CJ .A.-NlI-( C::II2h-NlI2 438.2 
L3 3 .A.c-C:: CJ .A. -NlI -( C:: II 2) 3-NlI2 521.5 
LJ 4 .A.c-.A.CJB-NlI-(C::II2)3-NlI2 438.2 
LJ 5 .A.c-BCJB-NlI-( C::II2)3-1'ffl2 422.2 
LJ 6 .A.c-C::CJ B-NlI-( C::II2)3-NlI2 505.2 
L3 7 .A.c-.A. CJC::-NlI-( C::II2h-NlI2 521.5 
L3 8 .A.c-B CJC::-NlI-( C::II2)3-NlI2 505.2 
LJ 9 .A.c-C:: CJC::-NlI -( C::II 2) 3-1'ffl2 588.4 
LJ 10 .A.c-.A..A.-NlI-(C::II2)3-1'ffl2 397.3 
LJ 11 .A.c-B.A.-NlI-( C::II2h-1'ffl2 381.3 
LJ 12 .A.c-.A.B-NlI-( C::II2)3-NlI2 381.3 
L3 13 .A.c-BB-NlI-( C::II2)3-NlI2 364.9 
LJ 14 .A.c-.A..A..A.-NlI-( C::II2)3-NlI2 537.1 
LJ 15 Ac-BBB-NlI-(C::II2)3-NlI2 489.2 
LJ 16 .A.c-C::CJCJQCJCJ .A. CJ-NII2 820.3 
Table 1.3 Library 3<29> from building blocks shown in Figure 1.6. 
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Figure 1.7 Structures of Compounds in Library 3<29). 
Library 3 was designed based on microcin B 17 (Figure 1.1. 7). 
Given that the thiazole, oxazole and bisheterocycle moieties may be essential 
to the antibacterial activities of microcin B 1 7, these moieties were 
systematically connected in a combinatorial library (library 3). 
Compounds L3 1-9 have a central glycine residue that separates the two 
heterocyclic moieties, which confers flexibility on the molecules. 
Compounds L3 10-13 have two heterocycles directly attached to each other 
giving it a certain degree of rigidity which is even higher in compounds L3 14 
and L3 15 with three heterocycles directly attached to each others. 
Compound L3 16 is a microcin B 17 fragment. 
Three combinatorial libraries with thiazole and oxazole-containing amino acids 
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that had been designed and synthesized were tested for cytotoxicity against the 
fish pathogen, Vibrio anguillarum, the enterobacterium Escherichia coli and 
the yeast Saccharomyces cerevisiae in cell culture growth inhibition assays and 
in zone inhibition assays. 
Zone inhibition assay is a classical method to screen antimicrobial agents. 
In zone inhibition assays, only the lethal activity of the antimicrobial 
compounds can be assessed after incubating the antimicrobial compounds with 
growing cultures of micro-organisms on agar plates for a period of 12-24 
hours. 
In cell culture growth inhibition assays on the other hand, both lethal and 
inhibit<!)ry effects of antimicrobial compounds can be determined. 
It has been reported that synthetic analogs of grarnicidin S antibacterial 
activities were highly dependent on the type of the assay used with 
growth inhibition assays showing greater activity against gram-negative 
bacteria than agar-based assays<30>. Factors such as variation in the diffusion 
rates of the compounds in the peptide libraries under screening may lead to 
different reported MIC values than cell culture growth inhibition assays. 
In this chapter, both zone inhibition assays and growth inhibition assays were 
used to screen the peptide libraries compounds but growth inhibition assay data 
was used to determine the MIC values. 
The selection of candidate micro-organisms followed that V. anguillarum 
causes vibriosis, a fish disease that causes severe economic losses. E. coli is 
an opportunistic enteric pathogen which causes enteric diseases in immunely 
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compromised humans, E. coli (ZK4) is a genetically engineered species that is 
microcin-sensitive which makes it a good selection to screen compounds in 
library 3 and compare their activities against microcin B 17. S. cerevisiae is a 
representative example of an eukaryotic micro-organism. 
Species selectivity of the antimicrobial activities of the combinatorial libraries 
against prokaryotic pathogens (V. anguil/arum and E. coli) and eukaryotic 
pathogens (S. cerevisiae) were also investigated. 
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1.2 EXPERIMENT AL 
Equipment 
Analytical HPLC experiments were performed on a Waters HPLC system 
which consisted of a gradient controller, two 501 pumps and a 486 tunable UV 
I VIS absorbance detector set at 220 run and a Vydac 218TP C 18 10 micron 
(250 x 4.6 mm I. D.) protein and peptide column. 
Scanning of the growth inhibition plates was done on a Dynex MRX, (Dynex 
Technologies Inc, VA). 
1.2.1 Zone Inhibition Assay 
Zone inhibition assays were done on E. coli (ZK4) and V. angu.illarum. 
E. coli (ZK4): 
E. coli (ZK4) was streaked from a frozen sample (-70°C) on a Luria Bertani 
(LB 10) medium and incubated at 3 7°C overnight. A string of individually 
growing colonies was collected with a sterile loop and put into 5 ml of 1 x LB 
10 in a sterile centrifuge tube. 
The solution was shaken at 37°C for 3 hours. The optical density (OD) was 
measured at 650 run and the dilution factor to give a bacterial concentration of 
2 x 103 colony-forming unit (cfu) I ml was calculated using the equation that 1 
OD at 650 run is equal to 2.5 x 108 cfu I ml. 
The bacterial suspension was inoculated into 0.1 x LB 10, 1 % agarose 
medium and poured into a petri dish. Peptide solution (5 µl) was added to the 
wells in the agar and incubated for 3 hours at 37°C. Full-strength LB 10, 1 % 
agarose medium was added on top of the previous layer and the plate was 
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incubated at 37°C overnight and the diameters of the observed zones of 
inhibition were measured. 
V anguillarum: 
V anguil/arum was streaked from a frozen sample (-70°C) on a Luria Bertani 
(LB 20) medium and incubated at 28°C overnight. A string of individually 
growing colonies was collected with a sterile loop and put into 5 ml of 1 x LB 
20 in a sterile centrifuge tube. 
The solution was shaken at 28 °C for 3 hours. The optical density (OD) 
was measured at 650 nm and the dilution factor to give a bacterial 
concentration of2 x 103 colony-forming unit (cfu) I ml was calculated using 
the equation that 1 OD at 650 nm is equal to 2.5 x 108 cfu I ml. The bacterial 
suspension was inoculated into 0.1 x LB 10, 1 % agarose medium and poured 
into a petri dish. Peptide solution (5 µl) was added to the wells in the agar and 
incubated for 3 hours at 28 °C. Full-strength LB 20, 1 % agarose medium was 
added on top of the previous layer and the plate was incubated at 28°C 
overnight and the diameters of the observed zones of inhibition were 
measured. 
1.2.2 Cell Culture Growth Inhibition Assay 
Cell culture growth inhibition assays were done on E. coli (ZK4), V 
" 
anguillarum and S. cerevisiae. 
E. coli (ZK4): 
E.coli (ZK4) was streaked from a frozen sample (-70°C) on a LB 10 plate and 
incubated at 37°C overnight. A string of individually growing colonies was 
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collected with a sterile loop and put into 5 ml of 1 x LB 10 in a sterile 
centrifuge tube. 
The solution was shaken at 37°C for 3 hours. The bacterial suspension was 
diluted with 0.1xLB10 to an OD of0.001 AU I ml at 650 nm. 
Diluted bacterial suspension was incubated with the peptide solutions (30 µl 
each) in the wells of a sterile 96 well plate for 3 hours at 37°C. 
The controls included blank controls (60 µl 0.1xLB10, no peptide and 
bacteria were added), positive growth controls (30 µl 0.1 x LB 10, 30 µl 
bacterial suspension), positive killing controls (30 µl of 0.5 M NaOH, 30 µl 
bacterial suspension). 
Full str~ngth LB 10 medium (100 µl) was then added to each well and the 
absorbance was measures at 570 nm at different time intervals. 
V anguillarum: 
V anguil/arum was strealfod from a frozen sample (-70°C) on a LB 20 plate 
and incubated at 28°C overnight. A string of individually growing colonies 
was collected with a sterile loop and put into 5 ml of 1 x LB 20 in a sterile 
centrifuge tube. The solution was shaken at 28°C for 3 hours. 
The bacterial suspension was diluted with 0.1 x LB 20 to an OD of 0.001 AU I 
ml at 650 nm. Diluted bacterial suspension was incubated with the peptide 
solutions (30 µl each) in the wells of a sterile 96 well plate for 3 hours at 
28°C. 
The controls included blank controls (60 µl 0.1 x LB 20, no peptide and 
bacteria were added), positive growth controls (30 µl 0.1 x LB 20, 30 µl 
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bacterial suspension), positive killing controls (30 µl of 0.5 M NaOH, 30 µl 
bacterial suspension). Full strength LB 20 medium (100 µl) was then added to 
each well and the absorbance was measures at 570 nm at different time 
intervals. 
S. cerevisiae: 
S. cerevisiae was streaked from a frozen sample (-70°C) on a YPD, 1 % 
agarose plates and incubated at 30°C overnight. A string of individually 
growing colonies was collected with a sterile loop and put into 5 ml of 1 x 
YPD broth in a sterile centrifuge tube. 
The solution was shaken at 30°C for 3 hours. The yeast suspension was 
diluted with 0.1 x YPD broth to an OD of0.001 AU I ml at 650 nm. Diluted 
yeast suspension was incubated with the peptide solutions (30 µl each) in the 
wells of a sterile 96 well plate for 3 hours at 30 °C. 
The controls included blank controls (60 µl 0.1 x YPD, no peptide and 
yeast added), positive growth controls (30 µl 0.1 x YPD , 30 µl yeast 
suspension), positive killing controls (30 µl of 0.5 M NaOH, 30 µl yeast 
suspension). 
Full strength YPD broth (100 µl) was then added to each well and the 
absorbance was measured at 570 nm at different time intervals. 
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1.2.3 HPLC Analysis 
HPLC analysis of peptide libraries was used to compare the hydrophobicities 
of the compounds in the libraries and to prepare serial dilutions of the 
compounds for antimicrobial testing. 
Peptide libraries 1, 2 and 3 were analyzed by RP-HPLC on a Vydac 
2 l 8TP C 18, 5 µ column ( 250 x 4.6 mm i. d., 300 A). 
Conditions: Linear gradient from 5% to 60% CH3CN over 40 minutes; solvent 
A consists of 5 % CH3CN aqueous solution, 0.1 % trifluoroacetic acid; solvent 
B consists of95 % CH3CN, 0.1 % trifluoroacetic acid, 1.37 % CH3CN I min; 
flow rate 1 ml I min; UV detection at 220 nm. 
The absorbance of the peptide peak at 220 nm represents the amount of peptide 
in a known injected volume of peptide solution and was used to calculate 
peptide concentrations. 
1.2.4 Media Preparation: 
Yeast extract, tryptone peptone (pancreatic digest of casein), YPD broth and 
YPD Bacto agar were from Difeo, sodium chloride (enzyme grade) was from 
Fisher. Distilled water was obtained from Milli-Q Plus PF system (Millipore). 
LBlO 
Yeast extract 5 g. 
Tryptone peptone 10 g. 
Sodium chloride 10 g. 
Add distilled water to 1 liter and autoclave at 120-124°C for 15 min. 
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LB20 
Yeast extract 5 g. 
Tryptone peptone 10 g. 
Sodium chloride 20 g. 
Add distilled water to 1 liter and autoclave at 120-124°C for 15 min. 
YPD broth 
Formula per liter 
Bacto yeast extract 10 g. 
Bacto peptone 20 g. 
Bacto dextrose 20 g. 
50 grams of YPD broth was dissolved in 1 liter distilled water and sterilized at 
120-124°C for 15 min. 
YPD Bacto agar 
Formula per liter 
Bacto yeast extract 10 g. 
Bacto peptone 20 g. 
Bacto dextrose 20 g. 
Bacto agar 15 g. 
50 grams ofYPD Bacto agar was dissolved in 1 liter distilled water and 
sterilized at 120-124°C for 15 min. 
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1.3 RESULTS AND DISCUSSION 
1.3.1 HPLC Analysis of Peptide Libraries 
Studies have shown a direct correlation between peptide hydrophobicities and 
the% CH3CN required to elute them from a reverse phase co1umn<31 >. 
The more hydrophobic peptides eluted at higher CH3CN percentage. 
Peptides in library 2 are arranged in order of decreasing retention times in 
Table 1.4. 
The number of L-3-(3-benzothienyl) alanine (S) residues was correlated with 
the hydrophobicity of the compounds in library 2. 
Compounds# 1 and# 9, Table 1.4, each contains 3 (S) residues and were the 
most hydrophobic compounds in the library followed by compounds # 2-5 and 
10-13 with 2 (S), and then# 6-8 and# 14-16 with 1 (S) residue. 
The presence of 2 histidine and 1 arginine residues makes compound # 8 and 
compound# 16 the least hydrophobic compounds in the library. 
Peptides in libraries 1 and 3 had overall lower retention times than did 
compounds in library 2. 
The% CH3CN required to elute compounds in libraries 1and3 ranged 
between 20-25 %. 
The lower % CH3CN correlated with the less hydrophobic nature of the 
building blocks used in libraries 1 and 3 compared to the more hydrophobic L-
3-(3-benzothienyl) alanine (S) residues used in the design of library 2. 
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Compound Sequence *Average % CH3CN at &220 
retention retention time. extinction 
time (min) coefficient (L 
mo1e·1 cm-1) 
Lil RSSS-NHi 31.8 49.6 44.03 
Li9 SSSR-NHi 29.7 46.6 46.24 
Li 3 RDSS-NHi 29.4 46.3 33.50 
L2 11 SDSR-NHi 27.7 43.9 36.95 
Li2 RLSS-NHi 27.4 43.4 33.50 
Li 10 SLSR-NHi 25.0 39.4 35.039 
Li4 RHSS-NHi 24.6 38.7 14.04 
Li 5 RSSH-NHi 23.4 37.2 41.57 
Li 12 SHSR-NHi 22.5 36.0 39.02 
Li 13 SSHR-NHi 22.4 35.8 50.84 
Li 7 RDSH-NHi 20.3 32.8 18.45 
Li15 SDHR-NHi 19.8 32.2 22.97 
Li 6 RLSH-NHi 17.6 29.2 17.46 
Li 14 SLHR-NHi 16.4 27.5 19.92 
Li16 SHHR-NHi 14.7 25.l 25.34 
Li 8 RHSH-NHi 12.0 21.5 23.31 
Table 1.4 Compounds of library 2 arranged in order of decreasing retention 
times. 
* An average of 2 runs. 
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1.3.2 Zone Inhibition Assay 
Compounds in library 2 were tested against E. coli ZK4 and V. angui/larum in 
a zone inhibition assay. Antimicrobial activity was tested using serial dilutions 
of the peptides, and the diameters of the zones of inhibition were measured 
after overnight incubation. As expected, the diameters of the zones of 
inhibition decreased with decreasing peptide concentrations. Tables 1.5.1, 
1.5.2, 1.6. l and 1.6.2 list the library 2 peptide concentrations and the measured 
zones of inhibition of E. coli ZK4 and V. anguillarum respectively. 
Sodium hydroxide and microcin B 17 were included in the zone inhibition 
assay as positive controls. 
The MIC* is considered to be the minimum amount of peptide that gives a 
zone of inhibition. 
For compounds in library 2, we also employed growth assays that were more 
sensitive than zone assays (section 1.3.3). The peptide concentrations tested in 
the zone inhibition assays were above the MIC values of peptides in library 2 
determined using the growth assay technique. 
The growth inhibition assays monitor the growth curves of bacteria after a 3 
hour incubation of the bacteria with the peptides. This approach aims to 
elucidate the mechanism by which these peptides exert their inhibitory effects 
on the bacteria. 
In a zone inhibition assay, the diameter of the clearing zone of inhibition 
corresponds to the bactericidal effects of the compounds tested. 
In a growth inhibition assay, the inhibition of bacterial growth is 
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monitored over a long period of time and the difference between bactericidal 
and bacteristatic effects can be observed. 
Library 1 contained enantiomeric and diastereomeric compounds that did not 
show any variation in their antimicrobial activities. They all had identical 
MIC* values of 4.5 µmoles, higher than MIC values of library 2 compounds. 
Library 2 tetrapeptide amides, (Tables 1.5.1, 1.5.2, 1.6.1 and 1.6.2), showed a 
higher antibacterial activities against E. coli (ZK.4) and V. anguillarum than did 
library 1 compounds. 
The concentration ranges that were tested in the zone inhibition assay were 
above the MIC values of the compounds in library 2. The activities of the 
library 2 compounds were comparable against E. coli and V. anguillarum. 
Cell culture growth inhibition assays were used to report MIC values of library 
2 tetrapeptide amides against E. coli, V. anguillarum and S. cerevisiae (section 
1.3.3). 
Library 3 compounds, at concentrations in the µmolar range and lower, were 
not able to produce measurable zones of inhibition against either E. coli ZK.4 
or V. anguillarum under the assay conditions. 
*MIC in zone inhibition assays denotes the peptide amount (µmoles) in the 
wells of the agar plates, and in cell culture growth inhibition assays, MIC 
denotes the peptide concentration (µmolar) incubated with the micro-organism 
cultures in the 96 well plate. 
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Compound M.W., Sequence Peptide Peptide Measured MIC 
g. I (µmoles (mg) zone of (µmoles 
mol. ) inhibition ). 
_{_mml*· 
Li 1 783.5 RSSS-NH2 28.1 22.02 6 
14.05 11.01 4 
2.81 2.20 4 <2.81 
Li 2 734.4 RLSS-NH2 6.19 4.54 8 
3.09 2.27 7 
0.62 0.45 6 <0.62 
Li 3 734.4 RDSS-NH2 6.19 7.40 12 
3.09 3.70 9 
0.62 0.74 3 <0.62 
Li4 717.6 RHSS-NH2 9.70 6.96 10 
4.85 3.48 8 
0.97 0.70 4 <0.97 
Li 5 717.6 RSSH-NH2 28.90 20.74 10 
14.45 10.37 8 
2.89 2.07 4 <2.89 
Li 6 668.5 RLSH-NH2 13.06 9.00 4 
6.53 4.50 0 6.53 
1.30 0.90 0 
Li 7 668.5 RDSH-NH2 13.79 9.21 10 
6.89 4.60 10 
1.37 0.92 6 <l.37 
Li 8 651.7 RHSH-NH2 17.88 11.65 16 
8.94 5.83 10 
1.78 1.17 8 <l.78 
Table 1.5.1 Measured zones of inhibition of peptides Li 1-Li 8 on E. coli ZK.4 
12 hours after incubation. 
* The well diameter was subtracted from the measured zone of inhibition 
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Compound M.W. Sequence Peptide Measure Peptide MIC 
g. / (µmoles d zone of (mg) (µmoles 
mol. ) inhibitio ) 
n_{_mml*· 
Li 9 783.5 SSSR-NH2 29.50 10 23.11 
14.75 6 11.56 
2.95 6 2.31 <2.95 
Li 10 734.4 SLSR-NH2 23.84 10 17.51 
11.92 7 8.76 
2.38 4 1.75 <2.38 
Li 11 734.4 SDSR-NH2 25.15 6 18.50 
12.58 4 9.25 
2.52 4 1.85 <2.52 
Li 12 717.6 SHSR-NH2 27.18 12 19.5 
13.59 10 9.75 
2.72 6 1.95 <2.72 
Li 13 717.6 SSHR-NH2 35.42 8 25.41 
17.71 8 12.71 
3.54 6 2.54 <3.54 
Li 14 668.5 SLHR-NH2 14.89 8 10.00 
7.45 NO 5.00 7.45 
1.49 NO 1.00 
Li 15 668.5 SDHR-NH2 17.18 8 11.50 
8.59 6 5.75 <8.59 
Li 16 651.7 SHHR-NH2 19.44 10 12.70 
9.72 10 6.35 <9.72 
Table 1.5.2 Measured zones of inhibition of peptides Li 9-L2 16 on E. coli 
ZK.4 12 hours after incubation. 
* The well diameter was subtracted from the measured zone of inhibition. 
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Compound M.W. Sequence Peptide Measure Peptide MIC 
g./ (µmoles d zone of (mg) (µmoles 
mol. ) inhibitio ) 
nJ.mml*· 
Li 9 783.5 SSSR-NH2 29.50 10 23.11 
14.75 6 11.56 
2.95 6 2.31 <2.95 
Li 10 734.4 SLSR-NH2 23.84 10 17.51 
11.92 7 8.76 
2.38 4 1.75 <2.38 
Li 11 734.4 SDSR-NH2 25.15 6 18.50 
12.58 4 9.25 
2.52 4 1.85 <2.52 
Li 12 717.6 SHSR-NH2 27.18 12 19.5 
13.59 10 9.75 
2.72 6 1.95 <2.72 
Li 13 717.6 SSHR-NH2 35.42 8 25.41 
17.71 8 12.71 
3.54 6 2.54 <3.54 
Li 14 668.5 SLHR-NH2 14.89 8 10.00 
7.45 NO 5.00 7.45 
1.49 NO 1.00 
Li 15 668.5 SDHR-NH2 17.18 8 11.50 
8.59 6 5.75 <8.59 
Li 16 651.7 SHHR-NH2 19.44 10 12.70 
9.72 10 6.35 <9.72 
Table 1.5.2 Measured zones of inhibition of peptides Li 9-Li 16 on E. coli 
ZK4 12 hours after incubation. 
* The well diameter was subtracted from the measured zone of inhibition. 
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Compound M.W. Sequence Peptide Peptide Measure 
g./ (µmoles (mg) d zone of 
mol. ) inhibitio 
n_(mml*· 
L2 1 783.5 RSSS-NH2 28.10 22.02 10 
14.05 11.01 8 
2.81 2.20 3 
L2 2 734.4 RLSS-NH2 6.19 4.54 6 
3.09 2.27 3 
0.62 0.45 0 
L2 3 734.4 RDSS-NH2 6.19 4.54 13 
3.09 2.27 8 
0.62 0.45 6 
L24 717.6 RHSS-NH2 9.70 7.00 10 
4.85 3.50 6 
0.97 0.70 4 
L2 5 717.6 RSSH-NH2 28.90 20.74 10 
14.45 10.37 6 
2.89 2.07 4 
L2 6 668.5 RLSH-NH2 13.06 8.73 10 
6.53 4.37 5 
1.30 0.87 0 
L2 7 668.5 RDSH-NH2 13.79 9.22 8 
6.89 4.61 6 
1.37 0.92 3 
L2 8 651.7 RHSH-NH2 17.88 11.65 10 
8.94 5.83 5 
1.78 1.17 1 
Table 1.6.1 Measured zones of inhibition of peptides L2 1-L2 8 on V 
anguillarum 12 hours after incubation. 
MIC 
(µmoles 
) 
<2.81 
0.62 
<0.62 
<0.97 
<2.89 
1.30 
<1.37 
<1.78 
* The well diameter was subtracted from the measured zone of inhibition. 
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M.W. Sequence Peptide Measured Peptide 
g./ (µmoles) zone of (mg) 
mol. inhibition 
_(mml*· 
L19 783.5 SSSR-NH2 29.50 8 23.11 
14.75 5 11.56 
2.95 2 2.31 
L1 10 734.4 SLSR-NH2 23.84 7 17.51 
11.92 3 8.76 
2.38 2 1.75 
L111 734.4 SDSR-NH2 25.15 6 18.50 
12.58 2 9.25 
2.52 0 1.85 
L1 12 717.6 SHSR-NH2 27.18 8 19.50 
13.59 5 9.75 
2.72 0 1.95 
L1 13 717.6 SSHR-NH2 35.42 8 25 .14 
17.71 6 12.57 
3.54 2 2.51 
L1 14 668.5 SLHR-NH2 14.89 7 9.95 
7.45 3 4.97 
1.49 0 1.00 
L1 15 668.5 SDHR-NH2 17.18 8 11.48 
8.59 6 5.74 
1.72 0 1.15 
L1 16 651.7 SHHR-NH2 19.44 8 12.67 
9.72 3 6.34 
1.94 0 1.27 
Table 1.6.2 Measured zones of inhibition of peptides Li 9-Li 16 on V. 
anguil/arum 12 hours after incubation. 
* The well diameter was subtracted from the measured zone of inhibition. 
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MIC 
(µmoles) 
<2.95 
<2.38 
2.52 
2.72 
<3.54 
1.49 
1.72 
1.94 
1.3.3 Cell Culture Growth Inhibition Assay 
The growth inhibition assay is a kinetic assay. Logarithmically growing 
cultures of E. coli, V anguillarum and S. cerevisiae were diluted into nutrient-
poor medium and pre-incubated with the peptides for 3 hours in 96-well plates, 
cultures were then diluted with nutrient-rich media and the bacterial growth 
was monitored by measuring the optical density at 570 nm. 
Controls in the assay included a freely growing bacterial suspension 
(positive control), and uninoculated medium (blank). To control for variability 
in the assay, the experiments were repeated on different days, and in each 
assay every peptide concentration was run in triplicate. 
Time points between 6 and 8 hours (9 and 11 hours post-exposure) were 
selected to measure the MI Cs of the peptides. 
For each peptide concentration, the average of the optical density in three wells 
was used to calculate the average optical density in the wells at each time 
point. A plot of the peptide concentration versus the % growth relative to the 
positive control was used to determine the MIC values. 
Table 1. 7 lists the results from library 2 peptides in order of decreasing activity 
against E. coli ZK4. Table 1.8 lists the results from library 2 peptides in order 
of decreasing activity against V anguillarum. Table 1.9 lists the results from 
library 2 peptides in order of decreasing activity against S. cerevisiae. 
The growth inhibition MIC values of peptides in library 2 against gram 
negative bacteria, E. coli and V anguillarum were comparable to each other 
but the activity against a fungus, S. cerevisiae showed a different pattern. 
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Peptides, L1 1 and L2 9 both with three L-3-(3-benzothienyl)alanine (S) 
residues, had a ten fold lower MIC values than peptides L2 14, L2 15 and L2 16 
with one (S) residue (Tables 1. 7 and 1.8). 
Compound M. W., g. I mol. Sequence MIC,µM. 
L1 l 783.5 RSSS-NH2 0.26 
L1 9 783.5 SSSR-NH2 0.26 
L1 2 734.4 RLSS-NH2 0.39 
.L2 3 734.4 RDSS-NH2 0.39 
L1 11 734.4 SDSR-NH2 0.42 
L1 13 717.6 SSHR-NH2 0.59 
L1 12 717.6 SHSR-NH2 0.70 
L1 10 734.4 SLSR-NH2 0.70 
L1 8 651.7 RHSH-NH2 1.30 
L1 5 717.6 RSSH-NH2 1.33 
L1 6 668.5 RLSH-NH2 1.64 
L1 4 717.6 RHSS-NH2 1.90 
L1 7 668.5 RDSH-NH2 2.00 
L1 16 651.7 SHHR-NH2 2.30 
L1 15 668.5 SDHR-NH2 2.50 
L1 14 668.5 SLHR-NH2 2.90 
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Table 1. 7 Antimicrobial activity of library 2 peptides against E. coli ZK4 
arranged in order of increasing MIC. 
Compound M. W., g. I mol. Sequence MIC, µM 
L2 1 783 .5 RSSS-NH2 0.16 
L2 9 783.5 SSSR-NH2 0.17 
L2 4 717.6 RHSS-NH2 0.65 
L2 12 717.6 SHSR-NH2 0.69 
-L2 11 734.4 SDSR-NH2 0.70 
L2 10 734.4 SLSR-NH2 0.74 
L2 16 651.7 SHHR-NH2 1.18 
L2 15 668.5 SDHR-NH2 1.30 
L2 14 668.5 SLHR-NH2 1.40 
L2 6 668.5 RLSH-NH2 1.60 
L2 5 717.6 RSSH-NH2 0.22 
L2 2 734.4 RLSS-NH2 0.27 
L2 3 734.4 RDSS-NH2 0.27 
L2 8 651.7 RHSH-NH2 0.41 
L2 13 717.6 SSHR-NH2 0.51 
L2 7 668.5 RDSH-NH2 0.52 
Table 1.8 Antimicrobial activity of library 2 peptides against V. anguillarum 
arranged in order of increasing MIC 
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Compound M. W., gram I mol. Sequence MIC, µM. 
Li 4 717.6 RHSS-NH2 1.10 
Li 1 783.5 RSSS-NH2 2.79 
Li 13 717.6 SSHR-NH2 3.22 
Li 5 717.6 RSSH-NH2 3.31 
Li 9 783.5 SSSR-NH2 3.63 
Li 11 734.4 SDSR-NH2 4.34 
-Li 2 734.4 RLSS-NH2 4.40 
Li 3 734.4 RDSS-NH2 4.73 
Li 12 717.6 SHSR-NH2 5.04 
Li 10 734.4 SLSR-NH2 5.34 
Li 6 668.5 RLSH-NH2 8.90 
Li 7 668.5 RDSH-NH2 9.32 
Li 16 651.7 SHHR-NH2 10.52 
Li 14 668.5 SLHR-NH2 10.80 
Li 15 668.5 SDHR-NH2 11.25 
Li 8 651.7 RHSH-NH2 17.15 
Table 1.9 Antimicrobial activity of library 2 peptides against S. cerevisiae in 
order of decreasing activity 
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Antibacterial activity also correlated with hydrophobicity, since the more 
hydrophobic peptides(Table 1.4) had lower MIC values. These patterns were 
not observed in the activity against S. cerevisiae. 
Increasing the number ofbenzothienylalanine residues did not correlate with a 
decrease in the MIC values. The MIC values of peptides in library 2 were 
generally ten folds higher against S. cerevisiae (Table 1.9) than against either 
E. coli or V. anguillarum (Tables 1. 7 and 1.8). 
The activity of peptides in library 2 against E. coli did not change by changing 
_ the position of arginine residue between the N and the C terminus for 
compounds L2 1, (RSSS-NH2), and L2 9, (SSSR-NH2). 
The interchange between L-3-(4-thiazolyl)alanine, (L), and D-3-(4-
thiazolyl)alanine, (D), at position two did not affect the activity of peptides in 
library 2 since peptide pairs L2 2 and L2 3, L2 14 and L2 15 had the same MIC 
values against E. coli while peptide pairs L2 10 and L2 11, L2 6 and L2 7 had 
less than two fold differences in their MIC values against E. coli. 
This pattern is also observed in the activity of peptides in library 2 against V. 
anguillarum. This pattern is lost in the activity of peptides in library 2 against 
S. cerevisiae. 
A second set of experiments were aimed at further characterization of the 
interactions of compound in library 2 with V. anguillarum. For this, we chose 
to test the most active compounds in library 2 L2 1, L2 2, L2 5 and L2 9. 
The MIC values were compared at 9 hours and 19 hours after incubating the 
peptide 
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solutions with growing cultures of V. angu.illarum (Table 1.10). 
Compound M.W.,g. Sequence 9 hours MIC, 19 hours 
I mol. µM MIC,µM 
L1 1 783.5 RSSS-NH2 0.34 ± 0.02 0.69 ± 0.01 
L19 783.5 SSSR-NH2 0.11±0.03 0.22 ± 0.03 
L15 717.6 RSSH-NH2 . 0.16 ± 0.02 0.32 ± 0.02 
L12 734.4 RLSS-NH2 0.54 ± 0.01 1.08 ± 0.01 
Table 1.10 Growth inhibition leading to calculated MIC values of library 2 
compounds at 9 hours and 19 hours against V. angu.illarum. 
The observed decrease in bacterial growth at 9 hours may be due to a 
bacteriostatic effect, where the peptides inhibit the growth of bacteria but the 
bacteria may recover. 
At 19 hours, the inhibition of growth of bacteria is more likely to be due to a 
bactericidal effect. The MIC values at 19 hours were two fold higher than 
those at 9 hours. 
Peptides in library 1 did not show variations in their antimicrobial activities 
against E. coli ZK4 and V. angu.illarum. The MIC values were consistently 
around 6.3 µM. 
Although members in library 1 were shown to bind DNA with different 
binding affinities(32>, this had no measurable effect on their activities against E. 
coli ZK4 and V. angu.illarum. 
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Library 3 peptides did not cause inhibition of the growth of either E. coli or V. 
anguillarum in the µmolar concentration range tested. Although the 
compounds in library 3 were designed analogs of a template natural 
antimicrobial peptide, microcin B 17, and incorporated certain 
elements of activity that are unique to the natural compound, this lack of 
potency compared with its naturally-occuring micrtemplate may be due to the 
larger size of microcin B 17 and additional intervening amino acids that may 
play a role in providing an optimum spacing between the heterocyclic-
. containing amino acid moieties. 
1.4 CONCLUSIONS AND FUTURE DIRECTIONS 
Library 2 was the most active library among the three libraries tested. 
The features that make library 2 more effective may be the presence of 
arginine residues and I or the benzothiophene moiety. 
It has been shown that poly-arginine peptides can help transport larger peptides 
across electrically charged membranes<33>. Bacterial membranes have a 
negative membrane potential as opposed to the electrically neutral eukaryotic 
membranes due to the nature and distribution of fatty acids in the lipid bilayer. 
The potency of library 2 peptides may be due to improved transport across the 
bacterial membranes as opposed to the less charged peptides in the other 
libraries. 
Benzothienylalanine residues have unnatural benzothiophene groups in their 
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side chains, which are aromatic planar and have the potential to intercalate 
between DNA base pairs. Intercalation can cause cytotoxicity 
due to topoisomerase inhibition. Arginine residues may also enhance 
localization of the peptide on the DNA by electrostatic attraction to the 
negatively charged phosphate backbone of DNA. 
In order to further investigate the mechanism of action of library 2 
peptides, the peptides were assayed for topoisomerase inhibition (Appendix A). 
Further directions include designing additional peptide libraries incorporating 
. more arginine residues and I or incorporating novel amino acid residues with 
side chains that can intercalate between DNA base pairs. 
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CHAPTER 2 ANTIMICROBIAL ACTIVITIES OF PLEUROCIDIN 
AMIDE AND RELATED PEPTIDES TRUNCATED AT THE C-
TERMINUS 
ABSTRACT 
Antimicrobial peptides (AMPs) are found in insects, fish and mammals 
where they play an integral role in the host defense mechanism against 
pathogenic micro-organisms. Many AMPs act via general permeabilization of 
the microbial membranes. So-called amphipathic a-helical peptides are an 
abundant and widespread class of AMPs. However, such short peptides are 
generally unstructured in solution, yet due to their cationic nature they are 
electrostatically attracted to negatively charged lipids and form a-helices in the 
microbial membrane. Two extensively-studied AMPs were isolated from 
insects. Cecropin A was isolated from the giant silk moth (Hylophora 
cecropia) while mellitin was isolated from bee venom (Apis mellifera) and 
unfortunately had a strong hemolytic toxicity. 
In order to maximize the antimicrobial activity while minimizing undesirable 
properties, such as hemolytic activity, several strategies have been used to 
develop novel AMPs. Amino acid residues can be deleted or substituted at 
either the N-terminus or the C-terminus. Hybrid formation of AMPs from 
different sources has been used to design cecropin - mellitin hybrids having 
increased antimicrobial activity and lower hemolytic toxicity. 
Pleurocidin is a 25-arnino acid peptide from the skin secretions of the winter 
flounder (Pleuronectes americanus). Pleurocidin could potentially form a 
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single well-defined amphipathic a-helix and exhibits no hemolytic activity. 
Previous SAR studies using pleurocidin have indicated that changing the C-
terminal carboxylic acid group to a C-terminal amide increases the potency 
(decreased the MIC value by 4 fold) against Vibrio angu.illarum. 
Given the small size of pleurocidin compared to other naturally-occuring 
AMPs, its lack of hemolytic activity, and its potential ability to form an 
amphipathic a-helix, we chose to further investigate the SAR of pleurocidin 
amide . 
. In this chapter, we describe the synthesis of two novel C-terminally truncated 
peptide amides derived from pleurocidin, pleurocidin amide, and CP-29, a 
cecropin-melittin hybrid. The antimicrobial activities of these peptides were 
explored against Vibrio angu,i//arum (wild type), a marine bacterium that 
causes vibriosis in fish, and Escherichia coli (ZK4), a microcin sensitive strain 
of E.coli. 
2.1 INTRODUCTION 
Problem Antibiotics are therapeutic agents, interfering with functions 
that are essential to bacterial growth or survival. Antibiotic resistance has 
become a major problem in the past decade<34)_ Bacteria can resist antibiotics 
as a result of chromosomal mutation or inductive expression of a latent 
chromosomal gene or by exchange of genetic material through transformation 
(the exchange of DNA), transduction (bacteriophage), or conjugation by 
plasmids<35)_ Streptococcus pneumonia, Streptococcus pyogenes and 
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Cecropins were the first AMPs to be characterized<40>. Cecropins are 
induced in the hemolymph of the pupae of the giant silk moth Hylophora 
cecropia following the injection oflive bacteria<40>. Cecropin A (Figure 2.1.1) 
is a 37 amino acid peptide amide with a basic N-terminal sequence and a 
hydrophobic C-terminal region <41 >. Mellitins (Figure 2.1.3) were isolated from 
bee venom and have a broad-spectrum antimicrobial activity, but are also 
unfortunately hemolytic<42>. Mellitins contain two helical regions, a basic C-
terminal region and an N-terminal hydrophobic region that are separated by a 
. flexible hinge region<42>. Pleurocidin (Figure 2.1.5) is a 25-amino acid peptide 
from the skin secretions of the winter flounder<43>. Pleurocidin is histidine rich, 
forms a single well-defined amphipathic helix and kills both gram-positive and 
gram-negative bacteria<43>. Pardaxins are excitatory toxins composed of 33 
amino acids and have been purified from the red sea Moses sole Pardachirus 
marmoratus and also from the western pacific Pardachirus pavoninus<44> 
(Figure 2.1.6). Pardaxins' effects have been attributed to its ability to form 
channels in cell membranes, thus interfering with ionic transport<44>_ Magainin 
I (Figure 2.1. 7) has been purified from frog skin secretions and was shown to 
exhibit wide spectrum activity against gram positive and gram negative 
bacteria< 45>. 
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Figure 2.1 Amino Acid Sequence and Edmundson Helical Wheels 
Projections<54 l of Antimicrobial Peptides 
Solid circles indicate hydrophobic amino acid residues, open circles indicate 
hydrophilic amino acid residues . 
2.1.l Cecropin A<4 0l 
H-KWKLFKKIEKVGQNIRDGIIKAGPAVAVYGQATQIAK-NH2 
I 
2.1.2 N-Terminus truncated and modified cecropin A(SO) 
H-WKLFKKILKVL- NH2 
L 
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2.1.3 Mellitin<42> 
H-GIGA VLKVL TIGLP ALISWIKRKRQQ-NH2 
2.1.4 MCFA, mellitin C-terminus with redistributed basic residues<51 > 
H-GLKKLISWIKRAAQQG-NH2 
46 
2.1.S Pleurocidin<43> 
H-GWGSFFKKAAHVGKHVGKAAL THYL-COOH 
cF 
H 
9 
K · 
2 
2.1.6 Paradax.in<44 > 
H:-GFF ALIPKlISSPLFKTLLSA VGSALSSGEQE-COOH 
s 9 
L 2 
2.1. 7 Magainin J_<45> 
H-GIGKFLHSAKKFGKAFVGEIMKS-COOH 
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2.1.8 CEME<49>, Hybrid of the first 8 amino acids of cecropin A and the first 18 
amino acids of mellitin 
H-KWKLFKKIGIGA VLKVL TTGLP ALIS-NH2 
2.1.9 CP-29 <52) 
H-KWKSFIKKLTTAVKKVLTTGLPALIS-NH2 
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Peptide synthesis Solid phase peptide synthesis (SPPS) was invented by 
R.B. Merrifield in 1963 to overcome the many problems of solution phase 
peptide synthesis<46). The desired sequence is assembled on an insoluble 
polymer support and subsequently cleaved off the polymer at the conclusion of 
the synthesis. Much research has been done since then to improve the type of 
polymer support, linkers, protecting groups, and the overall synthetic strategy. 
To avoid base-catalyzed racemization of amino acid residues during synthesis 
of the peptide chains, the peptide chains are synthesized from the C-terminus 
. to the N-terminus using N-protected amino acids. Coupling reagents such as 
DCC and HBTU have been shown to catalyze formation of amide bonds 
without racemization. At the end of the synthesis, a cleavage reagent such as 
hydrogen fluoride (HF) is typically utilized to simultaneously liberate the 
product peptide from the resin and remove the protecting groups. The HF is 
then completely removed under vacuum so that the crude deprotected peptide 
can be separated from the resin by dissolving it in aqueous solution, and 
lyophilizing it for further purification. A general scheme for solid-phase 
peptide synthesis is illustrated in Figure 2.2. In general, SPPS consists of 
attachment of the first amino acid via a linker onto the resin support, cycles of 
deprotection and coupling to assemble the amino acid residues in the correct 
order on the polymer support, and selective cleavage of the peptide from the 
resin and removal of the protecting groups. 
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Polymer Linker 
Polymer Linker 
Coupling 
Polymer Linker 
Polymer Linker 
Polymer Linker 
+ 
O R1-82 
II I 
HO-C-C-NH-8 I 1 
H 
j Attachment of the first amino acid 1.....-82 0 R 
H II I 
j 
l 
j 
j 
N-C-y-NH-81 
H 
Deprotection 
1.....-82 0 R 
H II I 
N-C-y-NH2 
H 
0 R2- 83 
II I 
HO-C-y-NH-81 
H 
0 R1_......820 R2_....83 
H II I H II I 
N-C-y-N-c-y-NH-81 
H H 
Cycles ofDeprotection and Coupling 
0 
H II 
N-C-
+ 
Protected Peptide 
(...__P_e_pt_id_e __ ~) 
R 1, R2 = Side chain groups, B2, B3, B4, B5 = side chain protecting groups 
B 1= N-terminus protecting group. 
Figure 2.2 Schematic Representation of Solid Phase Peptide 
Synthesis 
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The selection of the correct combination of an a-amino protecting group, a 
linker, and the side chain protecting groups is very important for the success of 
the synthetic scheme. The deprotecting agent used during stepwise synthesis 
should selectively remove the a-amino protecting groups without affecting 
side chain protecting groups. In our synthesis, the amino acids had t-Boc (t-
butyloxycarbonyl) (Figure 2.3) as the a-amino protecting group, and 50 % 
trifluoroacetic acid/CH2Ch was used as the deprotecting agent. The linker 
used in our experiment was p-methylbenzhydrylamine, and the resin was 
· polystyrene with 1 % divinylbenzene cross-linker (MBHA , 1 % DVB). In 
general, the insoluble polymer support for peptide synthesis is prepared via co-
polymerization of polystyrene and 1 % DVB for optimum swelling and 
mechanical stability. The peptide-resin linkage in a MBHA resin is p-
methylbenzhydrylamine (Figure 2.3.2), such that cleavage by hydrofluoric acid 
yields a C-terminal amide. Peptide C-terminal amides are desirable since 
amidation of the C-terminal carboxylic acid increases the net positive charge 
on the peptide, and offers extra hydrogen bonding sites for stabilizing the a-
helix. 
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CH3 0 I II 
H C-C-O-C-3 I 
CH3 
Polymer 
2.3 .1. t-Butyloxycarbonyl (Boe) group. 
(MBHA) linker. 
2.3.2. p-Methylbenzhydrylamine 
Figure 2.3. Structures of a- amino protecting group and resin-peptide linkage 
in SPPS. 
Prior SAR studies Solid phase peptide synthesis (SPPS) has been 
effectively utilized to synthesize cecropin A<47) and other AMPs with increased 
yields and effective purification of the active peptides from the reaction 
mixture. The overall potency and spectrum of activity of AMPs are influenced 
by the charge, the hydrophobicity, the degree of arnphipathicity and the % a-
helical content. Naturally occurring a-helical peptides vary in their cationicity 
and hydrophobicity. They have been found to have net positive charges 
varying from zero to + 16 at physiologic pH, however most of the peptides fall 
into the intermediate range ( 4 to + 6). Several studies have indicated that in 
peptides below that range, an increase in the positive charge of the peptides 
increased the overall antibacterial activity. Increasing the charge on peptides 
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within the optimum range has a minimal effect on the antimicrobial activity. 
Excessive charge can have a dramatic effect on the activity of the AMPs. It 
was shown that synthetic analogs of magainins with increased positive charge 
led to smaller, less stable, and shorter--lived pores, with faster translocation of 
the peptides through the membranes, leading to a lower antibacterial 
activitf48>. The percentage of hydrophobic residues may vary among naturally 
occurring antibacterial peptides but is generally found to be between 40%-
60%. Amphipathicity, the pattern of charged/hydrophobic residues in a 
. peptide, may be harder to define than charge or hydrophobicity, however most 
natural AMPs have a moderate to high amphipathicity. Structure Activity 
Relationship (SAR) analysis of the naturally occurring a-helical peptides aims 
at identifying the maximum possible antimicrobial activity accompanied by the 
minimum toxicity towards the host. One approach to SAR analysis is through 
sequence modifications by deleting, adding or substituting amino acids from 
either the N-terminus, or C-terminus. Helical wheel diagrams and structural 
studies indicate the presence of a hinge in cecropin A between two a-helical 
segments at residue #23C49>. Several studies have shown that it is possible to 
considerably reduce the size of the a-helical AMPs, while retaining their 
antimicrobial activity, thus simplifying their synthesis. A shortened version of 
cecropin A based on the N-terminal region (Figure 2.1.2) showed promising 
antimicrobial activityC50>. The peptide MCFA, designed based on the 15 amino 
acid residues from the C-terminus of mellitin, contained an extra glycine 
residue at the C terminus and had an interchange of pro 14 with lys, ala 15 with 
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lys, lys23 with ala and arg24 with ala, (Figure 2.1.4). MCF A exhibited 
comparable antimicrobial activity to the parent compound but had a 100-fold 
lower hemolytic activity than mellitin<51 ). Another design approach was 
through the formation of hybrids between different naturally occurring AMPs. 
Cecropin-Mellitin (CEME) was a hybrid of the first 8 amino acids of cecropin 
A and the first 18 amino acids of mellitin (Figure 2.1.8), and exhibited a better 
antimicrobial activity than either cecropin or mellitin alone, with no hemolytic 
effed49>. Further modifications in the amino acid sequence of CEME yielded 
. CP-29 (Figure2.l.9P2>. These modifications included interchange ofleu4 with 
ser, lys6 with ile, ile8 with lys, gly9 with leu, ile10 with thr, gly11 with thr, and 
leu14 with lys. CP-29 yielded a higher amphipathic a-helix content than 
CEME and gave a higher activity against gram-negative bacteria<52)_ 
Peptide design Pleurocidin is an extremely promising AMP first 
isolated in 1997. Pleurocidin is shorter (25 amino acid residues) than other 
natural AMPs (e.g.: cecropin A has 37 amino acid residues), forms a well-
defined amphipathic a-helix and exhibits antimicrobial activity with no 
hemolytic activity. In this work, CP-29 and pleurocidin amide were both 
synthesized using solid-phase methods, and served as positive controls in the 
antimicrobial assays. 
Pleurocidin amide 
H-GWGSFFKKAAHVGKHVGKAALTHYL-NH2 
CP-29<52) 
H-KWKSFIKKLTTAVKKVLTTGLPALIS-NH2 
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In this chapter, we describe the further investigation into the SAR of 
pleurocidin through design and synthesis of two new C-terminally-truncated 
peptide amides. Pleurocidin was chosen as a good lead compound for the 
design of novel AMPs due to its potent MIC against Vibrio anguillarum (0.76 
uM), absence of hemolytic toxicity, short length, and ability to form an 
amphipathic a-helix. The goal was to achieve improved antimicrobial activity 
while simplifying the synthesis by shortening the length of the peptide. 
Previous SAR studies on pleurocidin showed that addition of a lysine residue 
· to the N-terminus of pleurocidin did not enhance its antimicrobial activity 
against Vibrio anguillarum, but that formation of a C-terminal amide yielded 
an 8-fold increase in the activity of pleurocidin against Vibrio anguillarum <53 >_ 
SAR studies of AMPs that act through formation of pores through the bacterial 
membranes has shown that a minimum number of 15 amino acid residues is 
needed for the peptide to span the lipid bilayer of the bacterial membrane<51 >. 
The first designed peptide A, an 18 amino acid-long peptide amide starting 
from the N-terminus of pleurocidin should therefore be long enough to span 
the membrane. A comparison ofEdmundson<54>helical wheels and 
hydrophobicity plots (Kyte-Doolittle<55> ) of pleurocidin indicated that peptide 
A could potentially form an amphipathic a-helix, and the C-terminal amide 
should improve the stability of the helix. 
Peptide 1: H-GWGSFFKKAAHVGKHVGK-NH2 
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Upon comparing the sequence of pleurocidin to other AMPs with highly 
homologous sequences (e.g.: dermaceptin and ceratotoxins), the residues 19-21 
appear to be highly conserved, so a longer peptide B was designed to include 
them. The second designed peptide B, is a 21 amino acid-long peptide amide 
starting from the N-terminus of pleurocidin: 
Peptide 2: H-GWGSFFKKAAHVGKHVGKAAL-NH2 
To evaluate the effectiveness of the design, the antimicrobial activities of all 
. four synthetic peptides were evaluated using Vibrio angu.illarum (wild type) 
and Escherichia coli (ZK4). 
56 
2.2 Experimental 
Chemicals: 
Dimethylformamide (DMF), trifluoroacetic acid (TF A), dichloromethane 
(DCM), glacial acetic acid and N-methylpyrrolidinone (NMP) were purchased 
from Fisher. N, N '-diisopropyl ethylamine (DIEA), p-cresol and thiocresol 
were purchased from Fluka. Anhydrous hydrogen fluoride (HF) was 
purchased from Matheson. MBHA resin was purchased from Advanced 
ChemTech. HBTU reagent was purchased from Peptides International. 
Protected amino acids were purchased from Bachem Inc or Peptides 
International. 
Apparatus: 
Solid phase peptide synthesis was performed on a CS036 automated peptide 
synthesizer from CS Bio Co. Analytical HPLC experiments were performed 
on a Waters HPLC system which consisted of a model 680 gradient controller, 
two 501pumps,a486 tunable UVNIS detector, a Rheodyne injector, and a 
Vydac 218TP C1s protein and peptide column (10 um, 250 x 4.6 mm l.D.). 
Data was collected and analyzed using a model 1020 personal integrator and 
PE Nelson software (Perkin-Elmer Corp., USA). Preparative HPLC was 
performed using a miniPump® metering pump (thermo separation products, 
Riviera Beach, FL, USA) on a Vydac C18, (Nest Group, Southboro, MA, USA, 
15 x 1.2 cm). HF cleavage of the peptide was performed on a Model 2A HF 
apparatus (Immuno-Dynamics, La Jolla, CA, USA). Matrix-Assisted Laser 
57 
Desorption Time-of-Flight Mass spectrometry (MALDI-TOF MS) was 
performed at Harvard Microchemistry (Boston, MA, USA) on a PE 
Biosystems Voyager System 4074 (a-cyano-4-hydroxycinnamic acid matrix, 
700-5000 Da). Amino Acid Analysis (AAA) was performed on an Applied 
Biosystems 420 instrument at Harvard Microchemistry (Boston, MA, USA) 
using PTC amino acid derivatives normalized to alanine and phenylalanine. 
2.2.1 Synthesis 
MBHA resin, (1 g., sub 1.1 mmoles/g., 1 % DVB) was swollen overnight in 20 
ml DMF in an inverting type shaker. DMF was drained the next day, and the 
resin was washed with DCM (2 x 20 ml). The synthetic-program used in the 
synthesis of peptide 1, peptide 2, pleurocidin amide and CP-29 is shown in 
table 2.1. 
Step# Description 
1 Shake the resin with DCM, 15 ml for 5 min. 
2 Drain, shake the resin with 50 % TF A/DCM, 15 ml for 2 min. 
3 Drain, shake the resin with 50 % TFA/DCM, 15 ml for 28 min. 
4 Drain, wash the resin with DCM, 10 ml. 
5 Drain, wash the resin with 20 %DIEA/DCM, (2 x 10 ml). 
6 Drain, wash the resin with NMP (3 x 10 ml) 
7 Drain, add solution of 1 mmole of protected amino acid in 5 
mlDMF. 
8 Add 1 eq (1 mmole HBTU, 0.375 g.) dissolved in 5 ml DMF. 
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9 Add 5 ml with 20 %DIENDCM. 
10 Shake the reaction vessel for 30 min. 
11 Drain, wash with NMP (2 x 10 ml) 
12 Drain, wash with DCM (2 x 20 ml) 
13 Ninhydrin Test 
Table 2.1 Synthetic cycle used in the SPPS. 
Test for complete reaction: Ninhydrin Test<46>: 
The quantitative ninhydrin test was used to detect free amine groups at the N-
terminus of growing peptide chains on the resin. Free amine groups react with 
the ninhydrin reagent to give a blue-purple color (Rhuemann's purple) after 
heating at 100°C for 10 min. After a complete reaction cycle, the protected 
peptide-resin compound should have no free amine groups and give no blue 
color in the ninhydrin test if the coupling reaction went to completion. The 
ninhydrin test was carried out using two solutions: solution A and solution B. 
Solution A is prepared by mixing a solution of 40 g phenol in 10 ml absolute 
ethanol (warmed until the phenol is completely dissolved) and a solution of 2 
ml of 65% (W N) potassium cyanide (K.CN) in water and then diluting the 
mixture to 100 ml with pyridine. Solution B is prepared by dissolving 2.5 g. 
ninhydrin (0.28 M) in 50 ml absolute ethanol and is stored in the dark under 
nitrogen or argon. A clean dry glass pipette was used to transfer a small 
sample of the resin (-1 mg) into a test tube (14 x 100 mm). Four drops of 
solution A, followed by two drops of solution B were added to the resin 
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sample. The test tube was heated for 10 min. at 100°C. Absence of a blue-
purple color indicated a successful synthetic cycle(> 99.9 % coupling). Tables 
2.2, 2.3, 2.4 and 2.5 list the types of protected amino acids used for each 
peptide synthesis, and the number of amino acid coupling reactions required 
for each amino acid to achieve a complete reaction. In multiple couplings, 
(usually from the second coupling onward), 0.4 mmoles of the amino acid was 
used instead of 1 mmole to prevent waste. 
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Sequence Protected Coupling # of couplings 
Amino Acid Reagent Used 
K 1- Boe-Lys HBTU 4 
(Cl-Z) 
G 2- Boe-Gly HBTU 4 
v 3- Boe-Val HBTU 4 
H 4-Boe His, HBTU 3 
Dnp. 
K 5- Boe-Lys HBTU 3 
(Cl-Z) 
G 6- Boe-Gly HBTU 3 
v 7-Boe-Val HBTU 3 
H 8- Boe-His, HBTU 2 
Dnp. 
A 9-Boe-Ala HBTU 2 
A 10- Boe-Ala HBTU 2 
K 11- Boe-Lys HBTU 2 
(Cl-Z) 
K 12- Boe-Lys HBTU 2 
(Cl-Z) 
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F 13-Boc-phe HBTU 2 
F 14- Boc-phe HBTU 2 
s 15- Boe-Ser HBTU 2 
(0-Benzyl) 
G 16-Boc-Gly HBTU 2 
w 17- Boc-Trp HBTU 2 
G 18-Boc-Gly HBTU 2 
Table 2. 2 Peptide 1 synthesis: Protected amino acid building blocks used, 
number of couplings needed to achieve a negative ninhydrin test. 
Sequenc Protected Coupling Reagent Used #of 
e Amino Acid couplings 
L 1- Boe-Leu HBTU 5 
A 2-Boc-Ala HBTU 5 
A 3- Boe-Ala HBTU 4 
K 4-Boc-Lys HBTU 4 
(Cl-Z) 
G 5- Boc-Gly HBTU 4 
v 6-Boc-Val HBTU 4 
H 7-Boc-His, HBTU 4 
Dnp 
K 8- Boc-Lys HBTU 3 
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(Cl-Z) 
G 9- Boc-Gly HBTU 3 
v 10- Boe-Val HBTU 3 
H 11- Boe-His, HBTU 3 
Dnp 
A 12- Boe-Ala HBTU 3 
A 13- Boe-Ala HBTU 2 
K 14- Boc-Lys HBTU 2 
(Cl-Z) 
K 15- Boc-Lys HBTU 2 
(Cl-Z) 
F 16- Boc-Phe HBTU 2 
F 17- Boc-Phe HBTU 2 
s 18- Boe-Ser HBTU 2 
(0-Benzyl) 
G 19- Boc-Gly HBTU 2 
w 20-Boc-Trp HBTU 2 
G 21- Boc-Gly HBTU 2 
Table 2. 3 Peptide 2 synthesis: Protected amino acid building blocks used, 
number of couplings needed to achieve a negative ninhydrin test. 
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Sequence Protected Coupling Reagent Used # of couplings 
Amino Acid 
L 1- Boe-Leu HBTU 4 
y 2- Boe-Tyr HBTU 4 
H 3- Boe-His-Dnp HBTU 4 
T 4- Boe-Thr ( 0- HBTU 3 
Benzyl) 
L 5-Boe-Leu HBTU 4 
A 6-Boe-Ala HBTU 3 
A 7-Boe-Ala HBTU 3 
K 8- Boe-Lys (Cl- HBTU 3 
Z) 
G 9- Boe-Gly HBTU 3 
v 10- Boe-Val HBTU 3 
H 11- Boe-His, HBTU 2 
Dnp 
K 12- Boe-Lys HBTU 2 
(Cl-Z) 
G 13- Boe-Gly HBTU 2 
v 14- Boe-Val HBTU 2 
H 15- His, Dnp, HBTU 2 
Boe 
A 16- Boe-Ala HBTU 2 
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A 17- Boe-Ala HBTU 2 
K 18- Boc-Lys HBTU 1 
(Cl-Z) 
K 19- Boc-Lys HBTU 1 
(Cl-Z) 
F 20-Boc-Phe HBTU 1 
F 21- Boc-Phe HBTU 1 
s 22- Boe-Ser ( 0- HBTU 1 
Benzyl) 
G 23- Boc-Gly HBTU 1 
w 24- Boc-Trp HBTU 1 
G 25- Boc-Gly HBTU 1 
Table 2.4 Pluerocidin amide synthesis: Protected amino acid building blocks, 
number of couplings needed to achieve a negative ninhydrin test. 
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Sequence Protected Coupling Reagent Used # of couplings 
Amino Acid 
s 1- Boe-Ser ( 0- HBTU 4 
Benzyl) 
I 2-Boe-Ile HBTU 4 
L 3-Boe-Leu HBTU 4 
A 4-Boe-Ala HBTU 3 
p 5-Boe-Pro HBTU 4 
L 6-Boe-Leu HBTU 3 
G 7-Boe-Gly HBTU 2 
T 8- Boe-Tbr ( 0- HBTU 2 
Benzyl) 
T 9- Boe-Tbr ( 0- HBTU 2 
Benzyl) 
L 10- Boe-Leu HBTU 2 
v 11- Boe-Val HBTU 2 
K 12- Boe-Lys .(Cl- HBTU 2 
Z) 
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K 13- Boe-Lys (Cl- HBTU 2 
Z) 
v 14- Boe-Val HBTU 2 
A 15- Boe-Ala HBTU 2 
T 16- Boe-Thr( 0- HBTU 2 
Benzyl 
T 17- Boe-Thr-0- HBTU 2 
Benzyl 
L 18-Boe-Leu HBTU 2 
K 19- Boe-Lys (Cl- HBTU 2 
Z) 
K 20- Boe-Lys (Cl- HBTU 2 
Z) 
I 21- Boe-Ile HBTU 2 
F 22- Boe-phe HBTU 2 
s 23- Boe-Ser HBTU 2 
K 24- Boe-Lys (Cl- HBTU 2 
Z) 
w 25- Boe-Trp HBTU 2 
K 26- Boe-Lys (Cl- HBTU 2 
Z) 
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Table 2.5: CP-29 synthesis: Protected amino acid building blocks used, 
number of couplings needed to achieve a negative ninhydrin test. 
2.2.3 Deprotection and Cleavage from the Resin Support : 
After the last synthetic cycle was complete, the protected peptide-resin was 
washed with DCM (2 x 20ml), transferred to a clean manual peptide synthesis 
reaction vessel and dried under vacuum overnight. The dried resin was 
weighed and the yield of the crude protected peptide was calculated. Peptide 
1, wt. of the peptide-resin= 2.65 g., crude protected yield= 48%. Peptide 2, 
wt. of the peptide-resin= 2.71 g., crude protected yield= 46.6%. Pleurocidin 
amide, wt. of the peptide-resin= 2.95 g., crude protected yield= 44.4%. CP-
29, wt. of the peptide-resin= 3.2 g., crude protected yield= 48%. 
Dinitrophenol (Dnp) Removal: Dnp was used as the protecting group for the 
imidazole side chains of the histidine residues of peptide A, peptide B and 
pleurocidin amide. The Boe-protected peptide-resin in the reaction vessel 
was shaken with a mixture of thiophenol and DMF ( 4.5 ml, 5 ml) for 6 hours at 
room temperature to remove the Dnp groups. The resin was washed 
successively with DMF ( 4 x 20 ml), DCM ( 4 x 20 ml) until there was no 
yellow color in the drained liquid. t- butyloxycarbonyl (Boe) group Removal: 
Following the removal of Dnp, the pepide-resin was subsequently treated with 
10 ml of 50 % TFAIDCM for 30 min., then the resin was washed with DIEA 
(2 x 20 ml), and i-propanol (2 x 10 ml). The peptide-resin was then transferred 
to the HF reaction vessels (PF A Teflon) and dried overnight under vacuum. 
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2.2.4 HF Cleavage: 
The HF treatment was done in an HF apparatus, and simultaneously 
accomplished the cleavage of the peptide from the resin, the removal of the 0-
benzyl protecting group on serine, and the removal of Cl-Z protecting group on 
lysine. p-cresol (0.5 ml), p-thiocresol (0.5 ml) scavengers were added to the 
dry resin and 9 ml of anhydrous HF was condensed in the vessel at -50°C in a 
bath of i-propanol and C02cs)· The vessel was then warmed to 4°C and the 
mixture was stirred for 1 hour on ice. The HF was subsequently evaporated 
away with the aid of nitrogen (the HF was trapped with KOH) and then with 
water aspirator. 
2.2.5 Peptide Purification: 
Following HF treatment, peptide-resins were typically washed with 5 ml ether 
to remove most of the scavengers and protecting groups, and then extracted 
first with 10 ml of 10 % acetic acid (fraction A) and subsequently with 10 ml 
of glacial acetic acid (fraction B). The combined peptide extracts A and B 
were lyophilized and then re-dissolved in a minimum volume of 10 % acetic 
acid for gel filtration chromatography. The concentrated peptide extract was 
loaded on a Sephadex® G-25 column (31 cm x 3 cm). The crude peptide was 
eluted with 10 % acetic acid, flow rate 1.5 ml/min., UV-detection at 254 nm. 
Fractions (3 ml each) were collected and the initial fractions representing 
excluded material were pooled and lyophilized (Peak A in Figure 2.4). The 
crude peptide was then dissolved in deionized water and was analyzed by 
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Figure 2.4 Peptide 1, peptide 2, pleurocidin amide and CP-29 elution profiles from 
Sephadex®G-25 gel filtration chromatography. 
Volume of eluent (ml.) and absorbance (AU). 
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hydrophobic gradient HPLC on a Vydac 218TP C18 column (10 um, 250 x 4.6 
mm I. D). Solvent A: 5 % CH3CN I H20, 0.1 % TFA; solvent B: 85 % CH3CN 
I H20, 0.1 % TFA; linear gradient from 5%-85% CH3CN; 2.0 % CH3CN I 
min., 1 ml I min., absorbance measured at 220 run. The crude peptides were 
then purified using preparative isocratic HPLC and analyzed using MALDI-
TOF mass spectrometry. 
Peptide 1: The analytical gradient HPLC chromatogram of crude peptide 1 is 
shown in Figure 2.5. The most intense peak (designated by an arrow in Figure 
2.4) eluted at 35% CH3CN, and was selected to be purified by preparative 
HPLC. Figure 2.6. l shows the isocratic HPLC chromatogram of crude peptide 
.1 at 25%. Preparative HPLC was run by first preparing a concentrated solution 
of the crude peptide in 10% acetic acid (20 mg/mL), and then injecting 3 mL 
aliquots onto the preparative column, eluted isocratically at a flow rate of 9 
mL/min. in 25% CH3CN/H20, 0.1 % TF A. 3 mL fractions were collected and 
evaporated using a speed-vac centrifuge to first remove the acetonitrile and 
TF A. Fractions corresponding to peaks I and II, were then pooled and 
lyophilized to obtain fluffy solids. Purified peak II, expected to be the desired 
peptide, was further analyzed by MALDI-TOF MS. Purified peptide weight: 
350 mg, overall yield= 18%. 
Peptide 2: The analytical HPLC chromatogram of crude peptide 2 is shown in 
Figure 2. 7. The peak designated by an arrow (3 7% CH3CN) was selected to be 
purified by preparative HPLC. Preparative HPLC was performed at 27 % 
CH3CN, 0.1 % TFA (Figure 2.8.1). Fractions corresponding to Peak IV in the 
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chromatogram shown in figure 2.8.1 were evaporated to remove acetonitrile, 
pooled, and lyophilized. Figure 2.8.2 shows purified peptide 2. Purified 
peptide 2 was further analyzed by MALDI-MS. Purified peptide weight: 400 
mg, overall yield = 20 %. 
Pleurocidin: The analytical HPLC chromatogram of crude pleurocidin 
amide is shown in Figure 2.9. The peak designated by an arrow (44% 
CH3CN) was selected to be purified by preparative HPLC. Preparative HPLC 
was performed at 28 % CH3CN I H20, 0.1 % TFA (Figure 2.10.1). Peak II in 
_the chromatogram shown in Figure 2.10.1 was collected and analyzed by 
analytical HPLC (Figure 2.9.2) and by MALDI-MS. Purified peptide weight= 
700 mg, overall yield = 25 %. 
CP-29: The analytical HPLC chromatogram of CP-29 is shown in Figure 
2.11. The peak designated by an arrow (67% CH3CN) was selected to be 
purified by preparative HPLC (Figure 2.12.1). Peak III in the chromatogram 
shown in Figure 2.12.1 was collected and analyzed by analytical HPLC (Figure 
2.12.2) and by MALDI-MS. Purified peptide weight= 600 mg., overall yield 
=20%. 
2.2.6 Antimicrobial assays: Assays were carried out by Tarquin Dorrington 
in Professor Marta Gomez-Chiarri' s laboratory at URI similarly to those 
described in chapter 1. 
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2.12.1 Isocratic HPLC Analysis of Crude CP-29, 
prior to preparative HPLC 
Conditions: Vydac Cl8, 62 % CHiCN I H20, 0.1 % TFA 
ill- Peak of interest. 
2.12.2 Purified CP-29, after preparative HPLC 
Conditions: Vydac Cl 8, 5-85 % CH1CN over 40 min. 
Figure 2.12 Preparative HPLC Analysis of Crude CP-29 
2.3 RES UL TS AND DISCUSSION 
Peptide Synthesis Four solid-phase syntheses of peptide amides ranging 
from 18-26 amino acids were completed without premature termination in 2-3 
days each. Judging by increases in the weight of the resins, the yields of 
protected peptides ranged from 44.4% for pleurocidin amide, 46.6% for 
peptide 2 to 48% for peptides 1 and CP-29. Following HF deprotection, 
cleavage from the resin, and gel filtration chromatography to remove 
scavengers and protecting groups, the crude product mixtures were 
characterized using analytical gradient HPLC. It is clear that the same 
synthetic protocol can lead to variable success in obtaining the desired peptide. 
The soiid-phase method yielded more than one peptide species in some crude 
product mixtures and this was indicated by the multiple peaks observed in the 
analytical gradient HPLC chromatograms that were obtained following gel 
filtration. Peptide 2 (Figure 2.7) gave the cleanest chromatogram for a crude 
product, and therefore it seems that this synthesis went most smoothly. 
Peptide 1 (Figure 2.5) also showed one predominant product, although the 
overall chromatogram was not as clean. Analytical HPLC chromatograms of 
crude product mixtures from the syntheses of pleurocidin amide (Figure 2.9) 
and CP-29 (Figure 2.11) contained a significant number of additional peaks, 
some products having similar retention times to the largest peak, and therefore 
presenting possible purification problems. 
Peptide 1 was extracted from the resin following HF cleavage using 10% 
acetic acid, applied to a gel filtration column and the first peak that eluted from 
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the column (Sephadex® G-25 column, exclusion ~5,000 Da) was collected and 
lyophilized to give a yellow solid. In case the peptide was not sufficiently 
soluble in 10% acetic acid, the same resin was then re-extracted with glacial 
acetic acid, the extract applied to the same gel filtration column and the first 
peak was collected and lyophilized to give a white solid. Both excluded peaks 
were then combined and injected onto the HPLC for analysis of the crude 
product (Figure 2.5). By experimenting with isocratic conditions on the 
analytical column, the separation shown in figure 2.6. l was achieved using 25 
% acetonitrile. The crude peptide in peak II was then isolated using a 
preparative HPLC column eluted using 25 % acetonitrile. Individual fractions 
were re-injected on the analytical HPLC column before pooling those fractions 
containing peak IL The purity of the final product was calculated to be 84% 
based on HPLC, because some of peak I was still present. 
Peptide 2 was processed in the same manner to achieve >99% purity as shown 
in figures 2.8. l and 2.8.2. Peptide 2 eluted at 37 % CH3CN in the gradient run 
from 5-85 % CH3CN and was then purified using 27 % CH3CN. 
Pleurocidin amide was purified to >99% purity using 28 % CH3CN (figure 
2.10.2), and eluted at 44 % CH3CN in the gradient run (figure 2.9). 
CP-29 was purified to 90% from the crude product of the CP-29 synthesis, 
peak IV eluted at 67 % CH3CN in the gradient run, and was purified at 62 % 
CH3CN (figures 2.11 and 2.12). 
2.3.1 MALDI-MS 
Matrix-assisted laser desorption ionization (MALDI) time of flight (TOF) mass 
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spectrometry is a relatively new mass spectrometry technique. It has rapidly 
evolved as a valuable tool for the detection and characterization of 
biopolymers such as peptides, proteins, oligonucleotides and oligosaccharides. 
The use of laser beams to induce ionization without matrix assistance was 
more or less restricted to small biomolecules (below 1000 Da) bearing 
aromatic residues. The basic rational to employ matrices for MALDI-TOF MS 
was to assist in the ion formation of large biomolecules. The matrix candidate 
should be water soluble, not too volatile and chemically not aggressive. a-
Cyano-4-hydroxycinnamic acid has been used successfully as a matrix for 
MALDI. One of the most important conditions for the matrix to work well is 
an inti'mate mixing of the analyte and the matrix. Optimal molar ratios range 
from 1: 1000 to 1: 10,000 (analyte to matrix) so that the analyte molecules are 
singularized and fully surrounded by the matrix molecules. The absence of 
fragmentation peaks in MALDI-TOF MS suggests the high ion stability of 
[M+Ht under the experimental conditions. 
The identity of the peptides synthesized was determined by MALDI-TOF MS 
in the following manner. First, the predicted monoisotopic masses and M+H 
ions of the synthetic peptides were calculated using Peptide companion® 
software from CoshiSoft/Peptide search (Tucson, AZ). The monoisotopic 
molecular weight is the weight for the peptide formula containing exclusively 
12C, 1H, 14N, and 160 isotopes. The relative abundance of 12C is 98.90%, mass 
12 exactly and 13C is 1.10%, mass 13.00336. The relative abundance of 1H is 
99.985%, mass 1.00783 and 2H is 0.015%, mass 2.01410. The abundance of 
82 
14N is 99.63%, mass 14.00310 and 15N is 0.37%, mass 15.00001. The 
abundance of 160 is 99.76%, mass 15.99490 and 180 is 0.2%, mass 17.99900. 
Therefore, mass spectra are expected to show multiple peaks provided the 
resolution is adequate, with relative intensities depending upon the molecular 
formula. Table 2.6 lists the calculated monoisotopic molecular weights and 
corresponding expected M+H values for peptide 1, peptide 2, pleurocidin 
amide and CP-29. 
Peptide MW*(AMU) Abundance of MW 
M M+l M+2 M+3 
Peptide 1 1939.07 46.1 % 47.3% 6.32% 0.21% 
Peptide 2 2194.23 39.4% 51.0% 7.5% 2.0% 
Pleurocidin Amide 2708.48 35.4% 55.6% 8.6% 0.2% 
CP-29 2869.79 33.3% 54.87% 8.7% 3.0% 
Table 2.6 Calculated monoisotopic* molecular weights, and relative isotopic 
abundances for Peptide 1, Peptide 2, Pleurocidin amide and CP-29. 
Matrix-assisted laser desorption time-of-flight mass spectrometry (MALDI-
TOF MS) was then performed on HPLC purified samples of peptide 1, peptide 
2, CP-29, and pleurocidin amide. The mass spectrometry results for 
pleurocidin amide, peptide 1, peptide 2, and CP-29 are tabulated in Table 2.7. 
83 
MALDI-TOF Measured m./z Assignments M ± x MW* 
Results +H 
Pleurocidin amide 2731.5736 +22.0936 
2710? +1 
2709.61 0 2709.4 
2688.583 -21.0713 8 
2561.1896 -148.2912 
1396.8377 -1312.6423 
Peptide A 1816.1853 +23.0274 
1793.1579 0 1793.0 
(Peptide 1 - Phe) 1736.1237 -56.9209 0 
1707.1456 -86.0123 
1665.0406 -128.1173 
Peptide 2 2465.2273 +270.9973 
2218.0110 +22.8715 
2198.1294 +3 
2197.1294 +2 
2196.1347 +l 
2195.1586 0 2195.2 
2094.039 -101.1906 3 
2067.9396 -127.2904 
1296.6936 -898.536 
Peptide B 6105.33 +3305.5812 
5504.31 +2704.5631 
(CP-29 - Ala) 2921.14 +121.3935 
2902.58 +102.8324 
2884.71 +84.9530 
2850.04 +50.2921 
2797.41 -2.3400 2799.7 
2726.85 -72.9200 5 
2695.47 -104.2810 
2384.96 -414.7912 
*Calculated monoisotopic molecular weight, calculated using Peptide 
companion·® software from CoshiSoft I Peptide search (Tucson, AZ). 
Table 2.7 MALDI-TOF results for purified synthetic peptides Pleurocidin 
amide, Peptide A, Peptide 2, and Peptide B corresponding to sequences for 
pleurocidin amide, peptide 1(-Phe), peptide 2, and CP-29(-Ala). 
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The identities of purified synthetic peptide 2, peak IV, and synthetic 
pleurocidin amide, peak II were both confirmed by MALDI-TOF MS to have 
the expected molecular weights (Table 2.7). For synthetic peptide 2 (Table 
2. 7) the peak at 2196.134 7 corresponds to the calculated mass of the M+ 1 +H 
isotopic ion, and the peak at 2218.0110 corresponds to the calculated mass of 
the M+ 1 +Na which should be the largest intensity peaks around the molecular 
ion according to the calculations in table 2.6 (M = 39.4% and M+l = 51.0% 
isotopic abundance). The peak at m/z 2067.9396 is likely a fragment 
containing the first 20 amino acids (calc. M+H= 2067.45) to due cleavage of 
the C-terminal Leu-NH2 . The peak at 2094.0394 is likely a valine deletion 
peptide and the one at 2067.9396 is likely a lysine deletion peptide. The peaks 
at 2465 and 1296 could not be assigned to any likely intact peptide and may be 
fragments or incompletely deprotected peptides. The mass spectrum of 
pleurocidin amide was pretty clean, with the base peak at the molecular ion at 
2709.6065 (calc. M+H = 2709.48). There was a small peak at 2561.1896 
corresponding to the phenylalanine deletion peptide and 1396.8377 
corresponding to the fragment pleurocidin (13-25) amide. 
The actual mass of peptide A was less than the expected mass for peptide 1, 
indicating that the major product of the synthesis was likely a deletion peptide. 
The difference between the found mass (1793.15) and the expected mass 
( 1940.07) could indicate the loss of a phenylalanine residue giving a deletion 
peptide with a calculated mass of (1793.00) for the M+H ion which is in close 
agreement with the measured m/z (1793.15). No other amino acid deletion 
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could give the observed mass. Since the only two phenylalanine residues are 
fortunately located adjacent to one another in the sequence of peptide 1, the 
synthetic product could be unambiguously identified as a 1 7 amino-acid 
peptide having the sequence: 
Peptide A (Peptide 1-des-5 or 6Phe) 
H-GWGSFKKAAHVGKHVGK-NH2 
Peptide B, peak III also had less than the expected mass of CP-29. An alanine 
residue was probably deleted in the synthesis of CP-29 although the calculated 
mass still differs from the measured one by two mass units (Table 2.8). 
Monoisoto_l!_ic Mass M+H 
CP- Calculated 2869.79 2870.79 
29 * 
Found 2796.41 2797.41 
CP-29-Ala* 2798.6 2799.6 
Table 2.8 Monoisotopic Masses and M+H of CP-29 and Peptide B (CP-29 -
Ala?). Calculated, the masses were calculated using Peptide companion® 
software from CoshiSoft I Peptide search (Tucson, AZ). The sequence of CP-
29 contains two non-adjacent alanine residues, however the loss of either one 
of alanine residues should not affect the formation of an amphipathic a-helix. 
The two possible sequences are shown below. 
CP-29 (-Ala) H-KWKSFIKKLTTVKKVLTTGLPALIS-NH2 
H-KWKSFIKKLTTAVKKVLTTGLPLIS-NH2 
2.3.2 Peptide Quantification For Antimicrobial Assays: 
Amino acid analysis 
Weighing peptides accurately is a problem due to the presence of moisture and 
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uncetainties about counter ions and salts. To accurately report MIC values of 
the synthesized AMPs, we used amino acid analysis (AAA) of peptide 2 to 
calculate the extinction coefficients of peptide solutions. AAA was performed 
following acid hydrolysis of peptide 2. 
PITC-AA Ser Gly His Ala Val Leu Phe Lys 
Peak area I 0.76 4.20 2.10 4.00 1.50 0.98 1.95 3.33 
Ave. (1) (4) (2) (4) (2) (1) (2) (4) 
(Ala+Phe) 
(calc) 
Table .2.9 Amino acid analysis (AAA) of acid hydrolysate of purified peptide 2 
Monitoring integrity of synthetic peptides 
HPLC analysis was used to determine the purity and concentration of each 
peptide solution used in the antimicrobial assays. The extinction coefficient 
(E22o) of peptide 2 was calculated from the AAA data using Beer's law 
A=E*b*c. A solution of peptide 2 (100 µl) was acid hydrolyzed using 12 N 
HCL 25 µl was subsequently derivatized using PITC method. The residue 
was brought up in 40 µl distilled water and 6 µl was injected in the HPLC 
system for quantification. The amount of peptide 2 (8450 picomoles) was 
normalized. to phenylalanine and alanine. HPLC analysis of the intact peptide 
solution of the same concentration showed an absorbance of 0.0065 AU I µl in 
the peptide peak indicating that peptide 2 has E220 0.3466 L *µmole- 1 * cm-1• 
Since absorbance (A) at 220 nm is primarily due to the amide bonds in the 
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backbone of the peptide, the number of amide bonds is proportional to the 
intensity of absorbance at 220 run. Therefore the E22o for any similar peptide 
can be determined by adjusting for the number of amide bonds. The data from 
AAA of peptide 2 was used to calculate an appropriate E220 and quantify 
peptide A, pleurocidin amide and peptide B using absorbance at 220 run. 
Peptide A Peptide 2 Pleurocidin amide Peptide B 
Number of 17 21 25 25 
amide bonds 
E220 0.2805 0.3466 0.4126 0.4126 
Table 2.10 Calculated extinction coefficients for synthetic peptides using the 
results obtained from AAA of an acid hydrolysate of peptide 2 and analytical 
HPLC results on the same solution. 
2.3.3 Antimicrobial activities of synthetic peptides: 
The synthetic peptide solutions were diluted and tested for their antibacterial 
activities against Vibrio anguillarum (wild type) and Escherichia coli (ZK4) in 
cell culture growth inhibition assays. The bactericidal activities of the 
synthetic peptides were explored by co-incubating peptide solutions, in serial 
concentrations, with the bacteria for a period of 48 hours. Table 2.11 lists the 
minimum inhibitory concentrations (MICs) and minimum bactericidal 
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concentrations (MBCs) in micromoles/L of the synthetic peptides against V. 
anguillarum and E. coli. Since V. anguillarum is a marine bacterium, the 
effect of salt on antimicrobial activity was also assessed. 
V. a~llarum E. coli 
MIC MIC (1.5 MBC MBC (1.5 MIC MBC 
%NaCl % NaCl) 
Peptide A 12.50 50 > 100 >200 200 >200 
Peptide 2 12.50 25 100 200 100 200 
Pleurocidin 6.25 50 25 50 25 100 
amide 
Tach~plesin 12.50 25 25 25 25 25 
Peptide B > 100 > 100 > 100 >200 >200 >200 
Table 2.11 MICs and MBCs of synthetic peptides against V. anguillarum and 
E. coli (µM). *MBC denotes Minimum Bactericidal Concentration, defined as 
the minimum peptide concentration where bacterial growth was not observed 
at 21 or 23 hours. 
MIC is the concentration where the growth of the bacteria is 50% of control at 
21 or 24 hours. MBC is the concentration where there is no bacterial growth 
after 21 or 23 hours. V. anguillarum cells were incubated at 22°C at an initial 
cell count (.105) cfu I ml for 21 hours. E. coli (ZK 4) cells were incubated at 
37°C at an initial cell count (105) cfu I ml for 23 hours. Bacterial cells were 
co-incubated with the peptides in 96-well plates at the indicated temperatures 
and times so that the effect of the peptide on the bacterial growth could be 
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assessed. Each peptide was assayed in duplicate at eleven different 
concentrations. In addition, tachyplesin, an antimicrobial peptide that acts via 
a different mechanism than pleurocidin was used as a control peptide. 
Bacterial growth was monitored by absorbance at 650 run. 
Conclusions 
Studies have shown that when gradients of increasing CH3CN are used to elute 
peptides adsorbed on a C18 column, the more hydrophobic peptides elute at a 
higher percentage of CH3C~31 >. Hydrophilic contaminants from the synthesis 
and HF cleavage should elute first, followed by the peptide products in order 
of increasing hydrophobicity. The largest peak, indicated by an arrow on each 
chromatogram, was selected for further characterization. In the case of 
pleurocidin, when the hydrophobicity of the peptide was evaluated using the 
Hopp-Woods algorithm, the C-terminal region was markedly more 
hydrophobic. Thus it was expected that peptide 1 would elute at a lower % 
CH3CN than peptide 2, and this was the case. 
Assuming that in each synthetic step, the reaction went to completion, the 
strongest intensity peak should correspond to the full length peptide, while 
other peaks likely represent failure sequences (deletion or terminated 
sequences), that are shorter than the desired product. Since each coupling 
reaction wa_s monitored during the synthesis using the ninhydrin test, and the 
next ainino acid was not added until the ninhydrin test was negative, this 
assumption seemed justified. Since the synthesis proceeded from the C-
terminus of the peptide, any failure sequences would contain the same pattern 
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of amino acids but would be shorter, and thus should elute before the desired 
full-length peptide. Incompletely deprotected peptides would be expected to 
be more hydrophobic, and thus elute later than the desired product. In the case 
of both peptide A and peptide 2, the largest peak was also the last significant 
peak to elute from the column, and was expected to be the full-length peptide. 
As confirmed by the MALDI-TOF results, this strategy worked well in the 
case of peptide 2, where peak IV in figure 2.8.1 had the correct molecular 
weight and amino acid analysis. In the case of peptide A, which turned out to 
be a deletion peptide, missing a phenylalanine residue at position 5, the desired 
product, peptide 1, would be expected to elute later than the failure sequence 
which'was purified and characterized. The mass spectrometry results showed 
that during the solid-phase synthesis of pleurocidin amide and it's analogs, 
there was a difficult coupling of one of the adjacent phenylalanines, which 
merits further study. The problem with the synthesis of CP-29 was more 
obscure, and c<.1.iuld be due to some problem with the peptide synthesizer or the 
HF cleavage process. 
In our experiments, peptide B was not active against either V. angu.illarum or 
E. coli. The literature reported value of the MIC for pleurocidin amide against 
V. angu.illarum is 0.74 µMC53>. Our value was 6.25 uM and we determined the 
MBC to be 50 uM. 
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CHAPTER 3: Synthesis of Novel Thiazole-Containing Amino Acid 
Building Blocks For Combinatorial Peptide Libraries. 
ABSTRACT 
Many thiazole and oxazole-containing natural products exert biological 
activities e.g.: anticancer, antiviral, antibacterial and antifungal activities. 
Thiazole and oxazole rings may be important pharmacophores in these 
compounds. One traditional approach to thiazole synthesis is through 
Hantzsch synthesis, a one hundred year old method. The Hantzsch approach 
requires prior preparation of thioamides, which involves several steps. The 
thioamides easily revert to nitriles upon heating. Despite the difficulty of 
preparing the starting materials, the Hantzsch cyclocondensation itself 
proceeds smoothly in high yields. 
In this chapter, we discuss the synthesis of a novel thiazole-containing amino 
acid building block: Methyl 2-S-(1 '-Boc-2'-phenylethyl) thiazole-4-
carboxylate. 
Our synthesis involved the formation ofBoc-phenylalanine-N-methoxy-N-
methylamine. Subsequent reduction by LiAL~ yielded Boc-phenylalaninal. 
Condensation of Boc-phenylalaninal with L-cysteine methyl ester yielded 
Methyl 2-(1 '-Boc-phenylethyl) thiazolidine-4-carboxylate, which was further 
oxidized by activated Mn02 in benzene to yield Methyl 2-(1 '- Boc-2'-
phen~lethyl) thiazole-4-carboxylate. 
3.1 INTRODUCTION 
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Many thiazole and oxazole-containing natural products exert important 
biological activities e.g.: anticancer, antiviral, antibacterial and antifungal 
activities. Thiazole and oxazole rings may be important pharmacophores in 
these compounds(!>. 
In this chapter, we describe the synthesis of a novel thiazole-containing amino 
acid building block: Methyl 2-S-(1 '-Boc-2'-phenylethyl) thiazole-4-
NHBoc 
~ H 
'· 
·c' 
Q-c( ){~ 
carboxylate (1). COOCH3 (1) 
One approach to the synthesis of thiazole rings is through Hantzsch synthesis 
( eq 3 .1 ), a one hundred year old method that, despite its antiquity, is still 
+ eq (3.1) 
The mechanism of Hantzsch synthesis involves initial nucleophilic attack by 
sulfur followed by cyclocondensation<56>. The Hantzsch approach requires 
prior preparation of thioamides, which involves several steps. The thioamides 
easily revert to nitriles upon heating. Despite the difficulty of preparing the 
starting materials, the hantzsch cyclocondensation itself proceeds smoothly in 
high yields . Another approach to thiazole rings involves the condensation of 
C-terminal aldehydes (2) prepared from the corresponding amino acids (5, 
R=amino acid side chain.) with L-cysteine methyl ester to form a thiazolidine 
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(3)<57 >_ Thiazolidines can be dehydrogenated by active manganese dioxide in 
the presence of pyridine in benzene to yield the Boc-thiazole amino acids (4). 
L-amino acids are not expected to undergo racemization when they are 
converted to aldehydes and then condensed with L-cysteine methyl ester<57>. 
The cyclocondensation is not stereospecific, and is expected to give a mixture 
of diastereomeric thiazolidines. 
R 
-::: 
BocHN.,..C-CHO 
I 
H 
L-Cys-OMe 
(2) Benzene 
B s BocHN""'~-i l,,,,,H (J) 
H H N~COOCH3 
j Mn02 Benzene 
~ Stt (4) socHN~T-{ ~ 
H N COOCH3 
The precursor aldehydes (2) of protected amino acids can be prepared via two 
different approaches. 
1) Oxidation of the C-terminal alcohols (6) of protected amino acids (Si58>. 
R R I CH3I, K.HC03 I BocNH-C-COOH (5) BocNH-C-COOCH3 I 
DMF I H H 
1 
NaBH4,LiCI 
THF, CiH50H 
R R 
I (CH3)iSO, Pyridine.S03 I (6) BocNH-C-CHO BocNH-C-CH20H 
I I 
H (C2H5)JN H 
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2) Direct reduction of the protected amino acids via the corresponding Weinreb 
N-methoxy-N-methylamine amides (7)<59>. 
R 
I DCC/DCM 
BocNH-C-COOH 
I 
H 
R 0 
I II ,CH3 
BocNH-C-C-N 
H '0CH3 
j 
R 
I 
BocNH-C-CHO 
I 
H 
Our synthesis of compound (1) is illustrated in Figure (3.1). 
:o 
H~ 
~C-COOH ----BocHN I 
H 
(10) 
0 (8) 
H2%' /CH3 
~C-CON 
BocHN I 'ocH H J 
0 H2~ 
~C-CHO 
BocHN I 
H 
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(9) 
(7) 
Figure 3.1 Synthetic Scheme of Methyl 2-S-(1 '-Boc-phenylethyl)thiazole-4-
carboxylate. 
3.2 EXPERIMENT AL 
Chemicals: 
Lithium aluminum hydride (LAH), N, 0-dimethylhydroxylamine 
hydrochloride, L-cystine methyl ester hydrochloride were purchased from 
Aldrich. N, N'-dicyclohexylcarbodiimide (DCC), manganese (IV) oxide 
(activated), N, N-diisopropylethylamine (DIEA) were purchased from Fluka. 
Diethyl ether and trifluoroacetic acid were purchased from Fisher. 
Dichkiromethane was purchased from Burdick & Jackson. Boc-L-
phenylalanine was purchased from Novabiochem. Silica gel 60 for column 
chromatography (70-230 mesh), (surface area 500 m2 lg., pore volume 0.75 
cm3/g.) and silica gel TLC plates F 254 were purchased from E. Merck. TLC 
developing system: hexane-ethyl acetate, TLC plates were visualized under 
UV (254 nm); then the plate was exposed to Ii vapors in ajar for 5 min. 
Apparatus: 
The 1H NMR spectra (90 MHZ) were obtained on a modified EM-390 Varian 
spectrometer (EFT-90-30, Anasazi Instruments Inc., Indianapolis, IN), and 
data was pFocessed with the NUTS program (Win 95 version, Acom NMR 
Inc., Fermont, CA). 
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Chemical shifts (8) are given in ppm from tetramethylsilane (TMS). 
Abbreviations for peak description ares= singlet, d =doublet, t =triplet, q = 
quartet, m =multiplet. 
Synthesis of methyl 2-(1 '-Boc-phenylethyl) thiazole-4-carboxylate (1). 
Boc-phenylalanine-N-methoxy-N-methylamine (8) 
To a well stirred solution of Boc-L-Phenylalanine ( 7 g, 0.03 mole) and N, N-
dicyclohexylcarbodiimide (DCC) ( 6.18g., 0.03 mole) in 100 ml 
dichloromehtane (DCM), was added N,N-diisopropyl-N-ethylarnine (DIEA) ( 
5.22 ml, 0.03 mole). After 5 min., a solution of 0, N-dimethylhydroxylamine 
HCl ( 3.4 g, 0.03 mole) in 100 ml of DCM was added to the above stirred 
solution. The reaction was monitored by TLC ( silica gel, hexane : ethyl 
acetate 1:1) Rr: starting material 0.45, product 0.34. After 30 min., the solution 
was filtered through a filter paper (Whatman no 1) to remove dicyclohexylurea 
(side product of the coupling reaction) and 100 ml of DCM was added to the 
filterate. The DCM layer was washed with 1 N HCl ( 4 x 250 ml), then 
saturated aqueous Na2C03 solution ( 2 x 250 ml) and finally with saturated 
NaCl solution (250 ml). The organic layer was dried over 3 g. ofMgS04 
overnight, filtered and concentrated under reduced pressure. The oily yellow 
residue was purified using silica gel column ( 20 cm x 0.5 cm), eluted with 
hexane: ethyl acetate (1: 1 ); fractions of 1 ml were collected and the appropriate 
fractions were pooled and evaporated under reduced pressure to yield a white 
solid ( 7.13 g., 0.022 mole). 
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Yield: 75%, 
1H NMR (CDCl3, 90 MHZ). 
Figure 3.2.8 ppm:7.25 (s, 5H), 5.38 (d,1.3 H), 5.00 (d, 0.9 H), 3.66 (s, 3 H), 
3.16 (s, 3 H), 3.00 (m, 2.3 H), 1.39 (s, 8.8 H). 
Boc-phenylalaninal (9) 
Boc-L-Phenylalanine-N-methoxy-N-methylamine (7.3 g., 0.023 mole) in 200 
ml anhydrous diethyl ether was stirred at room temperature for 15 min. under 
argon. Solid LiAlH.t was added in excess, more than 10 equivalents. After 30 
min., HCl (5%) was added gradually to the solution and stirred for 5 min. at 
room temperature. Organic solvents in the reaction mixture were removed 
under reduced pressure. The aqueous residue was extracted with DCM ( 4 x 
200 ml). The combined DCM extracts were washed with 1 N HCl (2 x 100 
ml), then with saturated Na2C03 (2 x 100 ml), and finally with saturated 
aqueous NaCl (100 ml) and dried over 2 g. ofMgS04 overnight and filtered. 
Evaporation under reduced pressure yielded a yellow oil (4.2 g., 0.017 mole). 
TLC Analysis: (silica gel, hexane : ethyl acetate 1: 1) Rr starting material 0.34, 
product 0.54. 
Yield: 74%, 
1H NMR (CDCh, 90 MHZ). 
Figure 3.3.8 ppm:9.05 (s, 0.92 H), 7.28 (s, 5 H), 5.30 (m, 0.76 H), 3.1(d,1.62 
H), 1.4 (s, 9.05 H). 
Methyl 2-(1 '-Boc-phenylethyl) thiazolidine-4-carboxylate (10) 
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Boc-phenylalaninal (2g., 0.008 mole) was dissolved in 100 ml DCM. A 
solution of L-cysteine methyl ester* (1.1 g., 0.008 mole) in DCM was added 
dropwise and the Mixture was stirred for 3 hours at room temperature. The 
DCM layer was evaporated under reduced pressure, and the residue was 
redissolved in 200 ml benzene, stirred for 30 min., then evaporated under 
reduced pressure. This process was repeated three times. After the final 
evaporation, TLC analysis (silica gel, hexane: ethyl acetate 1: 1) showed 
several spots, (Rr 0.45, 0.44, 0.1, 0) and the starting material was gone. The 
spots at 0.45, 0.44 are the two stereoisomers of the thiazolidine with one spot 
of higher intensity.The crude products were isolated using a silica gel column 
(22 crri x 0.7 cm), eluted with ethyl acetate: hexane (1:1). Appropriate 
fractions were collected, pooled and evaporated to remove the solvent to yield 
a pale yellow solid (2g., 0.005 moles). 
Yield: 63%, 1H NMR (CDCIJ, 90 MHZ), Figure 3.4. 8 ppm:7.28 (s, 5 H), 
3.90 (s, 2.9 H), 3.3 (d, 0.9 H), 3.1 (d, 1.62 H), 1.4 (s, 8.7 H). 
*Note: The L-cysteine methyl ester solution was prepared by dissolving (3.4 
g., 0.01 moles) of (H-Cys-OMe)2· 2HC1and2-mercaptoethanol (2.3 g., 0.03 
moles) in 50 ml distilled water, and stirring at room temperature for 20 min. 
Solid NaHC03, (0.84 g., 0.01 moles) was added and the reduced product 
extracted with DCM (2 x 100 ml), and evaporated under reduced pressure to 
yield an oily liquid. 
Methyl 2-(1 '- Boc-2'-phenylethyl) thiazole-4-carboxylate (1) 
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To a well stirred solution of methyl 2-(1 '- Boc-2'-phenylethyl) thiazolidine-4-
carboxylate in 100 ml benzene, l 0 ml pyridine, Mn02 (purchased as activated 
Mn02 from the manufacturer) was added in excess, more than 10 equivalents 
and the solution was refluxed at 70°C for 12 hours. TLC analysis of the 
reaction (silica gel, hexane: ethyl acetate,1 : 1) showed one new spot at Rr 
0.47 and the starting materials disappeared. The solution was filtered through a 
filter paper, Whatman no 1, and the organic solvent was evaporated under 
reduced pressure. White crystals of 1 were obtained by recrystallization from 
ethyl acetate and hexane. The synthetic scheme suffered a drastic decrease in 
yield in this step. In an attempt to improve the yields, Mn02 was sometimes 
suspended in benzene and the benzene was distilled off to remove any traces of 
moisture, however the yields ofthis reaction did not improve. (- 5-10 %). 
1H NMR (CDCIJ, 90 MHZ). 
Figure 3.5.8ppm: 8.1 (s, 0.9 H), 7.28 (s, 5 H), 3.90 (s, 2.9 H), 3.2 (d, 1.62 H), 
1.4 (s, 8.7 H). 
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3.3 RESULTS AND DISCUSSION 
The synthetic strategy reported in this chapter is a general method that can be 
used to prepare heterocyclic amino acids. Replacing Boe-phenylalanine with 
other Boe-amino acids, it can be used to synthesize additional thiazole-
containing amino acid building blocks for combinatorial library synthesis. The 
preparation of aldehydes via N- methoxy-N-methylamides is increasing in 
popularity due to the ease of preparation of amides and the selective reduction 
to form amino acid aldehyes<60). In the formation of the Weinreb amides, DCC 
is a classic coupling reagent used to form amides without racemization and the 
reaction finished within 10 min., the precipitation of dicyclohexylurea pushed 
the reaction forward.For the reduction of N- methoxy-N-methylamides to yield 
the amino acid aldehydes, the mechanism is thought to proceed through initial 
formation of a stable complex that is then hydrolyzed to give the aldehyde<59). 
0 
H2C (9) 
BocHN.,. C-CHO 
I 
H 
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APPENDIX Topo I, II Inhibition Of A Tetrapeptide Library 
ABSTRACT 
DNA topoisomerases are a class of enzymes that catalyze interconversions 
between topological isomers of DNA double helices. DNA topoisomerases are 
broadly classified into type I and type II. DNA topoisomerases are implicated in a 
large number of intracellular processes and inhibition of DNA topoisomerases is a 
target of anticancer drugs. DNA gyrase is a prokaryotic type II topoisomerase and 
drugs that inhibit DNA gyrase can be used as antibacterial drugs. 
In this section, we describe our methods to assay a library of tetrapeptides for 
topoisomerase I and topoisomerase II inhibition. In a topoisomerase inhibition 
assay; 'the active enzyme will relax supercoiled DNA, inhibition prevents 
relaxation. 
Increasing the inhibitor concentration should eventually completely inhibit DNA 
relaxation. The products are analyzed using agarose gel electrophoresis. Relaxed 
DNA has a bigger radius than its supercoiled counterpart, thus would migrate 
slower than supercoiled DNA in an agarose gel. The amount of relaxed DNA is 
quantitated by scanning the gel for the intensity of fluorescence of the relaxed and 
supercoiled DNA. Most of the tetrapeptides inhibited both topoisomerase I and II 
at the concentrations tested although the peptides were tested in different 
concentrations, the degree of inhibition of either topoisomerase I or II did not 
linearly correlate with the concentrations of the peptides. 
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4.1 INTRODUCTION 
DNA topoisomerases are a class of enzymes that catalyze interconversions 
between topological isomers of DNA double helices<61 >. DNA topoisomerases are 
implicated in a large number of intracellular processes. DNA topoisomerases 
relax supercoiled DNA strands. Replication is the best known process that 
generate positive supercoils during semi conservative replication of DNA <62>. 
Transcription is a second example of a cellularprocess that generates supercoils. 
DNA supercoiling has strong effects on DNA structure and its interactions with 
other molecules. It directly impedes processes like m-RNA synthesis and 
interferes with polymerase processivity<63>. DNA topoisomerases are broadly 
classified into two mechanistic types; DNA topoisomerase type I and DNA 
topoisomerase type II. Type I topoisomerases break and reseal only one DNA 
strand while type II DNA topoisomerases catalyze double strand breakage and 
rejoining in an ATP driven reaction<64). DNA topoisomerase I and II change DNA 
linking numbers in units of 1 and 2 respectively<65). 
Inhibition of DNA topoisomerases is increasingly becoming a target for anticancer 
and antibacterial drugs. In the presence of a topoisomerase poison, the enzyme 
loses its ability to relax supercoiled DNA. A prokaryotic type II topoisomerase, 
DNA gyrase, is unique to prokaryotes<66). DNA gyrase is an attractive target for 
selective antibacterial agents, such as fluoroquinolone antibiotics<61 l. 
Camptothecin, a clinically used anticancer drug inhibits human topoisomerase r<68l. 
In this section, we describe our methods to assay inhibition of DNA 
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topoisomerases I and II by sixteen compounds from a tetrapeptide library. In a 
topoisomerase inhibition assay, the active enzyme will relax supercoiled DNA, 
inhibition prevents relaxation. 
Increasing the inhibitor concentration should eventually completely inhibit DNA 
relaxation. The products are analyzed using agarose gel electrophoresis. Relaxed 
DNA has a bigger radius than its supercoiled counterpart, thus would migrate 
slower than supercoiled DNA in an agarose gel. The amount of relaxed DNA is 
quantitated by scanning the gel for the intensity of fluorescence of the relaxed and 
supercoiled DNA. 
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4.2 EXPERIMENT AL 
Apparatus 
E-C Midicell EC 350 electrophoretic gel system, with buffer container, two silver 
electrodes and a power supply, were purchased from E-C Apparatus Corp. (New 
York). Pippetters, 50 µl, 200 µland 1000 µl were purchased from Gilson (France). 
The heating block with a constant temperature controller was obtained from VWR 
Scientific Company. A Kodak digital camera; (DC 120 Zoom), 254 nm light table 
(Fotodyne Incorporated) and Kodak Digital Science lD software was recorded, 
visualized and used to analyze bands. Distilled water was obtained from Milli-Q 
Plus PF system (Millipore). 
Chemicals 
Tris-HCI, Tris-base, boric acid and dithiothreitol (DTT) were purchased from 
Fluka Chemie AG (Switzerland). Supercoiled DNA pBR322 (1 mg/ml) and 
Topoisomerase I (200 units, wheat germ) were purchased from Promega (WI, 
USA). Tetrapeptides were synthesized via the solid-phase synthesis. Agarose 
Low EEO was purchased from Fisher Scientific (New Jersey). Sodium chloride 
and ethylenediaminetetraacetic acid (EDT A) were from Sigma Chem. CO. (St. 
Louis, MO, USA). Magnesium chloride and glycerin (certified A. C. S.)were 
obtained from Fisher Scientific (New Jersey). Ethidium bromide (95 %) was 
purchased from Aldrich Chem. CO. (Milwakee, WI). 
PROCEDURES 
Buffers: 
1 x TEE Gel Buffer: 
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Tris Base 10.9 g, 89 mmoles. 
Boric Acid 5.5 g, 90 mmoles. 
EDTA 0.73 g, 25 mmoles. 
Distilled Water to 1 Liter, pH= 8.4. 
10 x Reaction Buffer for Topo I: 
Tris Base 1.97 g, 16 mmoles. 
Tris HCl 5.3 g, 33 mmoles. 
EDT A 0.029 g, 0.09 mmoles. 
Dithiothreitol 0.15 g, 0.97 mmoles. 
Add distilled water to 100 ml, pH = 7 .8. 
DNA plasmid dilution buffer: 
Tris Base 0.067g., 0.5 mmoles. 
Tris HCl 0.69 g., 4 mmoles. 
EDTA 0.29 g., 1 mmoles. 
Add distilled water to 100 ml, adjust pH to 7.4. 
Staining Solution: 
200 µl Ethidium Bromide ( 1 mg I ml) 
200 ml TBE buffer. 
Gel Preparation: 
1 % Agarose gels were prepared by heating 1 g. of agarose in 100 ml TBE buffer 
for 2 min., pouring the solution into gel plates and allowing the gel to cool down at 
room 
temperature. 
Topo I Assay: 
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The smallest effective concentration of topo I, which fully relaxed the supercoiled 
plasmid pBR322 was first determined, and then utilized in the topo I inhibition 
assay. The gel results for this determination are shown in figure 4.2.1, and the plot 
of enzymatic activity was linear up to 1.5 units (Figure 4.2.2). 20 units of enzyme 
caused a new product to form which had lower mobility than relaxed pBR 322. 
The smallest effective concentration of topo I required to unwind > 80 % of 0.05 
µg of plasmid in 30 min. at 37°C was 1 units. A unit is defined by the 
manufacturer as the amount of enzyme required to convert 1 µg of pGM® -9Zf(-) 
Vector DNA from supercoiled form to relaxed form in 30 min. at 3 7°C. 
Relax~tion Assay: 
In a clean autoclaved microcentrifuge tubes, 3 µl 10 x reaction buffer, 5 µl pBR 
(0.01 µg I µl), 2 µl topo I in several concentrations (such that total activity 20, 5.7, 
1.54, 0.86, 0.19 Units, dilutions of the enzyme were made in 50 % glycerol, 50 % 
10 x reaction buffer) were mixed (10 µl total), vortexed and incubated at 37°C for 
30 min. The reaction was stopped by adding 2 µl 30 % bromophenol dye and 10 
µl was loaded into the wells of the gel. The gels were run at 75 Volts, 15 
milliamps. at room temperature for 2 hours in 1200 ml TBE buffer. The gel was 
stained with ethidium bromide for 1 hour at room temperature. The bands were 
visualized by fluorescence on a UV light box, photographed with a digital camera 
and analyz€d using Kodak software. 
Topo I Inhibition by Tetrapeptides: 
Tetrapeptide solutions were prepared in several dilutions using 90 % 1 x reaction 
buffer, 10 % glycerol. In a clean micro-centrifuge tube, 1 µl of 10 x reaction 
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buffer, 2 µl of peptide solution and 2 µl of topo I (1 U/µl) were mixed, vortexed 
and incubated at 37°C for 10 min. 5 µl of pBR 322 DNA, (0.01 µg I µl) was 
added, the tubes vortexed and incubated at 37°C for 30 min. The reaction was 
stopped by adding 2 µl of 30 % bromophenol dye to each tube and 10 µl of the 
mixture was loaded into the wells of the gel. The gels were run at 75 Volts, 15 
milliamps. at room temperature for 2 hours in 1200 ml TBE buffer. The gel was 
stained with ethidium bromide for 1 hour at room temperature. The gel data for 
the inhibition assay is shown in figure 4.3. 
Topo II Assay: 
Topo IJ was purchased from USB Corp., (OH, USA). The smallest effective 
concentration to fully relax 0.02 µg supercoiled pBR322 was determined and used 
in topo II inhibition assays. The smallest concentration of topo II to fully relax 
supercoiled pBR322 was 1 unit. A unit is defined by the manufacturer as the 
amount of enzyme that fully relaxes 0.3 µg of negatively supercoiled pBR322 
plasmid DNA in 15 minutes at 30°C under standard assay conditions. The gel 
results are shown in figure 4.4. 
Relaxation Assay: 
Topo II reaction buffer was supplied by USB Corp. as 10 x concentrate (100 mM 
Tris, pH 7.9, 500 mM NaCl, 500 mM KCl, 50 mM MgCb, 1 mM EDTA, 0.15 
mg/ml BSA, 10 mM ATP). Topo II dilution buffer (10 mM sodium phosphate, pH 
7 .1, 50 mM NaCl, 0.2 mM DTT, 0.1 mM EDTA, 0.5 mg/ml BSA, 10 % glycerol). 
In a clean autoclaved centrifuge tube, 14 µl of distilled water, 2 µl of 10 x reaction 
buffer, 2 µl of DNA (0.01µg/µl),2 µl oftopo II (10, 5, 1, 0.1 units diluted in topo 
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II dilution buffer). The reaction was incubated at 30°C for 15 minutes. The 
reaction was stopped by adding 4 µl of dye solution (20 % bromophenol blue, 1 % 
SDS). 
The wells in the gel were each loaded with 20 µland the gels were run at 75 Volts, 
15 milliamps. for 2 hours in 1200 TBE at room temperature. The gels were 
stained for 1 hour with ethidium bromide at room temperature. The bands were 
visualized by fluorescence on a UV light box, photographed with a digital camera 
and analyzed using Kodak software. 
Topo II Inhibition by Tetrapeptides: 
In micro-centrifuge tubes, 12 µl of distilled water, 2 µl of 10 x reaction buffer, 2 µl 
of tetrapeptide solutions (serial dilutions in distilled water), 2 µl of topo II (1 unit) 
were mixed, vortexed and incubated at 30°C for 10 minutes. Supercoiled plasmid 
pBR322 (2 µl, 0.01 µg/µl) was then added and the reaction mixture was incubated 
at 30°C for 15 minutes. The reaction was stopped by adding 4 µl of dye 
solution(20 % bromophenol blue, 1 % SDS). 
Each well in the gel was loaded with 20 µl of the reaction mixture and the gels 
were run at 75 Volts, 15 milliamps. for 2 hours in 1200 TBE at room temperature. 
The gels were stained for 1 hour with ethidium bromide at room temperature. The 
bands were visualized by fluorescence on a UV light box, photographed with a 
digital camera and analyzed using Kodak software. 
The gel data for topo II inhibition by tetrapeptides are shown in figure 4.5, figure 
4.6, figure 4.7 and figure 4.8. 
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Figure 4.1 The sequences and building blocks oftetrapeptide library. 
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1. J ... ;, 'i 5 6 7 g 'I 
Lane Sample 
I Control, 0.05 l..ll! pBR 322 l 
2 0.05 µg pBR 322 + 20 units old lope I 
3 0.05 µg pBR 322 + 0.1 units old lope I 
4 0.05 IJl(jl_BR 322 + 20 units l~o I 
5 0.05 µg pBR 322 + 5.7 units topo 1-100% 
6 0.05 µg pBR 322 + l .54 units topo 1-100% 
7 0.05 µg pBR 322 + 0.86 units lOJl.O I 
8 0.05 µg pBR 322 + 0.19 units tOjl_O I 
9 0.05 µg pBR 322 + 0.09 units topo I 
Figure 4.2.1 Determination of the smallest effective concentration of topo I, which can 
fully relax 0.05 µg of the supercoiled plasmid pBR 322 in 30 min. at 37°C us ing I % 
agarose gel electrophoresis. 
N =Nicked plasmid pBR 322 
R =Relaxed plasmid pBR 322 
S = Supercoiled plasmid pBR 322 
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Tope I Enzyme concentration (Units) and% relaxed pBR 322. 
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Figure 4.2.2 Plot ofTopo I concentration and% relaxed pBR 322 
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Figure 4.3 Gel data on topo l inh ibiti on by tetrapeptides ( 1-16). 
Lane Inhibition Sam 
I 0.05 
2 0.05 
3 ND 0.05 # I 
4 ND 0.05 #2 
5 0 0.05 #3 
6 ND 0.05 #4 
7 + 0.05 #5 
8 + 0.05 
'9 ND 
10 + 
11 + 
12 + 
13 + 
14 + 
15 ++ 
16 ++ 
17 ++ 
18 ++ BR 322+2 units to 
19 Control, 0.05 BR 322 . 
20 BR 322. 
21 BR 322 . 
ND = noc decemuned. 
R =Relaxed plasmid pBR 322 
S = Supercoiled plasmid pBR 322 
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Figure 4.4 Detem1ination of the smallest effective concentration oftopo II, which can 
fully relax 0.02 µg of the supercoiled plasmid pBR322, using 1 % agarose gel electrophoresis. 
Lane Sam 
I 0.02 
2 0.02 
3 0.02 
4 0.02 
5 0.02 o [] I unit . 
6 0.02 o [] (0.1 units . 
R =Relaxed plasmid pBR 322 
S = Supercoiled plasmid pBR 322 
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Figure 4.5 Inhibition of topo n by tetrapeptides ( 1-4). 
R =Relaxed plasmid pBR 322 
S = Supercoiled plasmid pBR 322 
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2 3 4 s 6 7 8 9 
Lane Sample 
I 0.02 
2 0.02 
3 0 .02 1 unit . 
4 0 .02 
5 0.02 1 unit+ 
6 0.02 1 unit+ 
7 0.02 1 unit+ 
8 0.02 l unit+ 
9 0.02 
10 0.02 1 unit+ 
11 0.02 
12 0.02 1 unit+ 
13 0.02 1 unit+ 
14 0.02 
15 0.02 
Figure 4.6 Inhibition oftopo IT by tetrapeptides (5-8). 
R = Relaxed plasmid pBR 322 
S = Supercoiled plasmid pBR 322 
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Lane Sample Ratio of 
Supercoiled 
DNN 
(Supercoiled 
DNA+Relaxed 
DNA . 
I 0.02 82.8S % 
2 0.02 82.68 % 
3 0.02 I unit+ 84.77 % 
4 0.02 81.13 % 
s 0.02 66.89 % 
6 0.02 66.9% 
7 0.02 1 unit+ e 0% 
8 0.02 l unit+ 69.96 % 
9 0.02 1 unit+ 41.92 % 
10. 0.02 l unit+ 61.16 % 
11 0.02 l unit+ 36.32 % 
12 0.02 1 unit+ e 75.06 % 
13 0.02 1 unit+ 75.7 % 
14 0.02 49.S7 % 
IS 0.02 I unit. 2S.IS % 
Figure 4.7 Inhibition of topo Il by tetrapeptides (9-12) . 
R = Relaxed plasmid pBR 322 
S = Supercoiled plasmid pBR 322 
128 
I ·. . : ·. ·' 
. . ~ ·. 
12 13 14 15 
Lane Sample Ratio of 
Supercoi led 
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0.02 82.6 % 
2 0.02 80.1 % 
3 0.02 0% 
4 0.02 74.397 % 
5 0.02 66.79 % 
6 0.02 68.58 % 
7 0.02 76.81 % 
8 0.02 77.17 % 
9 0.02 43.77 % 
10 0.02 60.63 % 
11 0.02 79.9% 
12. 0.02 46.39 % 
13 0.02 25.71 % 
14 0.02 44.9% 
15 0.02 61.7 % 
Figure 4.8 Inhibition of to po IT by tetratpeptides ( 13-16) 
R =Relaxed plasmid pBR 322 
S = Supercoiled plasmid pBR 322 
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4.3 RES UL TS AND DISCUSSION 
The smallest effective concentration of topoisomerase I, which fully relaxed the 
supercoiled plasmid pBR322 was determined and then utilized in the topo I 
inhibition assay. Figure 4.2.1 shows the concentration dependant relaxation of 
pBR 322 by topoisomerase I.. The smallest effective concentration of 
topoisomerase I required to unwind > 80 % of 0.05 µg of plasmid in 30 min. at 
37°C was 1 units.Topoisomerase I inhibition assays by the tetrapeptide library 
compounds were based on the differential migration of supercoiled versus the 
relaxed forms of plasmid pBR 322 on a 1 % agarose gel under 75 volts, 15 
milliamps at room temperature for 2 hours. Figure 4.3 shows the result of this 
assay. Preliminary screening indicated that compounds in the tetrapeptide library 
inhibited topoisomerase I at micromolar concentrations. 
The smallest effective concentration of topoisomerase II, which fully relaxed the 
supercoiled plasmid pBR322 was determined and then utilized in the topo II 
inhibition assay. Figure 4.4 shows the concentration dependant relaxation of pBR 
322 by topoisomerase II. 
The ratio of supercoiled DNA concentration to the sum total of supercoiled and 
relaxed DNA concentrations was used to determine the degree of inhibition of 
topoisomerase II. The compounds were tested in serial concentrations. 
Figure 4.5 ~hows the inhibition oftopoisomerase II by compounds RSSS-NH2, 
RLSS-NH2, RDSS-NH2 and RHSS-NH2. Both RLSS-NH2 and RDSS-NH2 did 
not show inhibition of topoisomerase II in any of the concentration tested. Both 
RSSS-NH2 and RHSS-NH2 inhibited topoisomerase II at the concentrations tested 
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although the degree of inhibition did not linearly correlate with the concentrations 
used. Figure 4.6 shows the inhibition oftopo II by compounds RSSH-NH2, 
RLSH-NH2, RDSH-NH2, and RHSH-NH2. Peptides RLSH-NH2 and RDSH-
NH2 did not inhibit topoisomerase II at the concentrations used in the assay while 
RSSH-NH2 and RHSH-NH2 inhibited topoisomerase II but not in a concentration-
dependant manner. 
Figures 4.7 and 4.8 show the inhibition of topoisomerase II by SSSR-NH2, 
SLSR-NH2, SDSR-NH2, SHSR-NH2, SSHR-NH2, SLHR-NH2, SDHR-NH2 and 
SHHR-NH2. The concentrations tested did inhibit topoisomerase II activity 
althou~ the degree of inhibition did not linearly correlate with peptide 
concentrations. This might be due to that the concentrations used were higher than 
the linear concentration range. 
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